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ABSTRACT: 
 
Fite, Kristen Ph.D. Biomedical Sciences Ph.D. Program, Wright State University. 2017. 
Dysregulation of Phospholipase D (PLD) isoforms increases breast cancer cell invasion.  
 
 
 Breast cancer remains the second most prevalent cancer among women in the 
U.S. with metastatic breast cancer having the worst prognosis. A rapidly proliferating 
tumor under various stressors will promote phenotypic cellular changes, known as 
epithelial-to-mesenchymal transition (EMT), which allows cells to begin to invade 
surrounding tissue, enter the circulatory system, and eventually seed a distant metastatic 
site. The phospholipase D (PLD) enzymes are critical regulators of cell signaling 
pathways necessary for cell migration. While the importance of PLD enzymes in cancer 
cell invasion is well known, clinically applicable methods of PLD inhibition are not yet 
available.  
 The best-studied isoforms are the ‘classical’ PLD1 and PLD2 membrane lipases 
that hydrolyze phosphatidylcholine (PC) to free choline and phosphatidic acid (PA). PA 
acts as a secondary messenger activating numerous pathways leading to cell growth and 
proliferation, vesicle trafficking, and cell migration. PLD1 and PLD2 are upregulated in 
several cancers including breast and, furthermore, promote tumorigenesis and disease 
progression. However, the specific molecular mechanism that regulates overexpression of 
PLD1 and PLD2 in cancer remains unclear. I investigated post-transcriptional regulation 
of the classical PLD isoforms by microRNA (miRNA) in cancer cell invasion and in 
stress (nutrient starvation) leading to EMT. MicroRNA are currently widely investigated 
as potential therapeutic agents involved in a myriad of diseases. Naturally produced in the 
body, miRNA are attractive therapeutic molecules based on their small size, surprising 
stability, and potent regulatory capabilities.   
 A repertoire of four microRNAs present in non-cancerous breast cells that are 
down-regulated in invasive breast cancer cell were found and demonstration of their 
regulation of PLD1 or PLD2 mRNA was done by luciferase reporter assay. Exogenous 
addition of these microRNAs to invasive breast cancer cells reduced cell invasion. 
Additionally, initial nutrient starvation increased classical PLD protein levels, 
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concomitant with cell invasion. With prolonged starvation, PLD-targeting microRNA 
were upregulated and functioned in a negative feedback loop to downregulate PLD 
protein expression.  
 While much is known about the PLD1 and PLD2 isoforms, the other mammalian 
PLD isoforms (PLD3, PLD4, and PLD6) are vastly less studied. Interestingly, PLD6 has 
recently been found to be overexpressed in breast cancer tumors, however, further studies 
investigating the role of PLD6 in cancer progression have not been published.  PLD6 
localizes to the mitochondrial outer membrane and uses cardiolipin as a substrate to 
produce PA. This reaction promotes mitochondrial fusion, thereby inhibiting apoptosis, 
while increasing oxidative phosphorylation, both of which are critical to cancer 
progression. While PLD1 and PLD2 are ubiquitously expressed, PLD6 is expressed at 
lower basal levels in most tissues, making PLD6 an attractive therapeutic target, when 
upregulated in cancer, with potentially less adverse side effects.  
 The protein and gene expression of PLD6 are upregulated in invasive breast 
cancer cells compared to non-cancerous breast cells. PLD6 subcellular localization 
changed in response to invasion-promoting factors, nutrient starvation and EGF 
signaling. Furthermore, this is the first report showing that modulating PLD6 expression 
influences cell invasion of aggressive breast cancer cells.  
 Overall, I show that increased expression of PLD1, PLD2, and PLD6 in invasive 
breast cancer cells leads to higher cell invasion. A novel molecular regulation of classical 
PLD by a repertoire of microRNA was demonstrated. Additionally, PLD6 increases 
breast cancer cell invasion of certain breast cancer cell lines. This work highlights the 
importance that targeting PLD family members could have in breast cancer therapeutics.  
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CHAPTER 1. INTRODUCTION 
 
Breast Cancer Breast cancer is a leading cause of cancer related death in women 
worldwide (1-3). It is estimated that one in eight women in the U.S. will be diagnosed 
with breast cancer during their lifetime. Each year, half a million women lose their battle 
with breast cancer worldwide (4). While breast cancer incidence rates are relatively stable 
in the U.S., rates are rising in Europe, Latin America, Asia, and Africa (5). This is likely 
due to an increase in Western lifestyle including consumption of processed foods, 
physical inactivity, as well as changes in reproductive patterns such as delayed 
childbearing and having fewer children (5). Breast carcinoma can be classified generally 
as either carcinoma in situ or invasive carcinoma. Carcinoma in situ remains contained 
within the tumor boundaries, whereas invasive carcinoma has invaded the surrounding 
tissue with increased disease spread corresponding to an increase in tumor stage (6,7). 
Invasive carcinoma is further classified by histology with the most common being No-
special-type carcinoma (ductal). Ductal carcinomas are again further categorized by gene 
expression profiling and the five major types include Luminal A, Luminal B, Normal 
breast-like, Basal-like, and HER2 Positive. These five subtypes have clinical importance 
in their correlation with prognosis and response to therapy (6-8). Recent decades have 
produced tremendous improvements in the detection and treatment of breast cancer 
including increased public awareness as well as advancements in mammography (5).  
Remaining challenges in successful treatment of breast cancer include the treatment of 
triple negative breast cancer as well as drug resistance (5). Triple negative breast cancer 
is so named because cancer cells do not express the estrogen, progesterone, or HER2 
receptors. Targeting these receptors in other forms of breast cancer has significant 
clinical success and the lack of these receptors on triple negative cancer cells limits the 
therapeutic options for these patients.  
This study was primarily conducted in three different cells lines depicted in 
Figure 1. Two breast cancer cell lines were used including the high-invasive MDA-MB-
231 and the low-invasive MCF-7 ductal breast carcinoma cell lines. MDA-MB-231 cells 
are also classified as triple negative and claudin-low. Triple negative breast cancers 
generally have the worst prognosis and are the most difficult to treat clinically (5,9). 
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Claudin-low refers to low levels of cell-cell juntion proteins claudin and E-cadherin. This 
classification is usually seen in triple negative breast cancers and represents an invasive 
phenotype (5).  In contrast, MCF-7 cells are classified as estrogen receptor positive 
(ER+) and luminal subtype. This class of breast cancer is typically less aggressive and is 
responsive to estrogen-targeted therapy (5). The non-cancerous HMEC primary cell line 
was used as a control for non-cancerous human mammary epithelial cells.  
 
Epithelial-to-Mesenchymal Transition (EMT) and Metastasis The majority of breast 
cancer mortalities (>90%) are related to metastatic disease (10). Similar to other cancers, 
breast cancer metastasizes to distant organs including lungs (11,12), liver (12), bone (13), 
and brain (14). It was once thought that metastasis was a result of only prolonged disease 
progression, meaning a primary tumor grew to a certain size or duration of time and cells 
eventually metastasized. However, studies have documented cancer cell invasion and 
micrometastasis formation at very early stages of disease progression (15). Thus, 
understanding molecular mechanisms of metastasis is ever more pertinent. Metastasis 
begins in a growing tumor where cells are subjected to stressors, such as nutrient 
starvation and hypoxia if angiogenesis doesn’t match tumor growth. Tumor cells under 
stress enter a series of genetic and epigenetic changes called epithelial-to-mesenchymal 
transition (EMT) (16-18), wherein the cell adopts a less-differentiated and more invasive 
phenotype (19,20). These cells are able to invade the surrounding tissue eventually 
entering the circulatory system (blood or lymph circulation) and seed a distant site to 
form a metastatic tumor (19-21). Invasive cancer remains difficult to treat, fighting 
disseminated cells throughout the body. In addition, invasive cells have different 
phenotypes with a myriad of signaling pathways activated compared to the primary tumor 
cells (21).  
 EMT is a complex process, which requires a reprogramming of a cell. During 
development, EMT and its reverse process, mesenchymal-to-epithelial (MET), are critical 
in developing tissues (22). Cells undergoing EMT lose cell polarity as well as cell-cell 
adhesion and thus gain a more mesenchymal, or less differentiated, phenotype along with 
greater potential to migrate and invade surrounding tissue and additionally increased anti-
apoptotic potential (10,16-18). EMT involves genetic and epigenetic changes and several 
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transcription factors involved include Slug, Snail, Twist, and ZEB1/2 (16,22). 
Characteristic changes include the downregulation of cell adhesion proteins such as E-
cadherin, concomitant with the upregulation of mobility proteins such as vimentin. Thus, 
understanding the signaling pathways involved in invasive breast cancer cells remains 
critical to developing novel therapeutics.  
 
Phospholipase D The phospholipase D (PLD) enzyme family contains several 
mammalian isoforms all with a characteristic HKD motif in their catalytic site (23-27). 
Figure 2 summarizes the mammalian isoforms and their features. The classical PLD 
mammalian isoforms, known as PLD1 and PLD2, are the best characterized. They are 
ubiquitously expressed and are involved in numerous signaling pathways, particularly 
through their catalytic byproduct phosphatidic acid (PA) (23-27). Each isoform contains 
two HKD-containing catalytic domains that function together to hydrolyze the membrane 
lipid phosphatidylcholine into free choline and phosphatidic acid. The PLD enzymatic 
reaction is illustrated in Figure 3A. PA, is a negatively charged lipid and accumulation of 
it results in negative membrane curvature (23-27). This negative curvature promotes 
vesicle trafficking and lamellipodia formation in mobile cells. PLD2 localizes 
predominantly to the plasma membrane, while PLD1 localizes to cytoplasmic membranes 
(26,27).  
 PLD1 and PLD2 are vital enzymes in many tissue types, including healthy breast 
tissue, and their enzymatic products exert influence over an abundance of cellular 
pathways, including cytoskeletal rearrangement, membrane trafficking, and cell 
migration (26). The role of classical PLD in these signaling events also makes it integral 
to cancer cell metastasis (28-30). PLD plays an important role in maintaining the integrity 
of cellular membranes. Furthermore, increased PLD protein expression and enzymatic 
activity have been reported in multiple cancer types, including breast cancer (30-33) and 
K-Ras driven cancers (34-36). Additionally, classical PLD has been implicated in cellular 
signals that suppress apoptosis and contribute to cancer cell survival (27,37,38). Elevated 
PLD activity leads to activation of mammalian target of rapamycin (mTOR), a survival 
signal often hyperactivated in cancer (39,40) and also subdues the tumor suppressors p53 
and protein phosphatase 2A (38). Zheng et al. published a model for enhanced survival 
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and migration signals in the developing tumor (41). In a developing tumor mass, cells 
inside the mass were subjected to hypoxia and nutrient and growth factor deprivation. 
These stressed cells responded by elevating PLD protein levels and survived presumably 
by gaining the ability to migrate. While the classical PLD isoforms are involved in cancer 
progression, little is known about their protein regulation in healthy and cancerous 
tissues. 
Non-classical mammalian PLD isoforms include PLD3, 4, and 6, and are vastly 
understudied (42). PLD3 and PLD4 are transmembrane proteins that localize to the 
endoplasmic reticulum and Golgi, respectively (42). PLD6 localizes to the outer 
mitochondrial membrane where it uses cardiolipin as a substrate to produce phosphatidic 
acid, which is discussed further below. A mammalian PLD5 isoform has not been 
described.  
 
Phosphatidic Acid PA is a critical phospholipid within the cell. PA serves as the 
substrate for all membrane phospholipid biosynthesis, necessary to maintain membrane 
integrity as well as for cell growth and division (43,44). PA is also an important 
secondary messanger signal activating notable pathways including mTOR (43,45). 
Numerous proteins bind to PA and PA thereby functions to recruit proteins to membranes 
and promote cell signaling. There are three major pathways that produce PA. 
Lysophosphatidic acid acyltransferase (LPAAT) converts lyso-PA to PA. The PA 
produced from this pathway is converted to CDP-DAG (cytidine 5’-diphosphate 
diacylglycerol), which is used for phospholipid biosynthesis (43). Another pathway is 
conversion of dacylglycerol (DAG) to PA by diacylglycerol kinase (DGK). This DAG 
population is generated from triglyceride storage or PLC-mediated hydrolysis of 
PI(4,5)P2, and thus represents a smaller proportion of PA production within the cell. 
Finally, PA is produced by PLD-mediated hydrolysis of PC. While the PA produced from 
LPAAT is predominately used for general phospholipid synthesis, the DAG and PLD 
pathways produce PA that becomes secondary messanger signals. PLD and PLC-DAG 
pathways are activated by nutrients (46,47), growth signals (48), or stress (27,49) and 
often produce localized PA populations, which further activate signaling within the cell.  
 As mentioned above, one of the major pathways activated by PA is mTOR. Both 
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mTORC1 and mTORC2 interact with PA, thereby stabilizing mTORC (50). mTORC 
activation promotes cell growth while suppression of mTORC leads to cell cycle arrest in 
G1 (51,52). This is an important regulatory step within the cell cycle because mTORC 
senses the presence of essential amino acids and glutamine, which are necessary for 
protein synthesis in S phase of the cell cycle (51). Because PA stabilizes mTORC and PA 
is the substrate for de novo phospholipid biosynthesis, the PA-mTORC interaction likely 
functions as an additional nutrient signal (43). The availability of PA to interact with 
mTORC positively correlates with cell’s ability to synthesize phospholipids to generate 
new membranes during cell division. Furthermore, PA is also produced as a result of 
growth factor and nutrient signaling via PLD. Thus, PA signaling is likely important in 
cancer cells within a proliferating tumor.   
 
Phospholipase D6 Phospholipase D6 (PLD6) is also known as MitoPLD and Zucchini 
(Zuc). It is the smallest member of the mammalian PLD family at only 28 kDa. Along 
with a mitochondrial localization signal and a transmembrane domain, PLD6 contains the 
characteristic HKD (His-Lys-Asp) catalytic motif of the phospholipase D protein family 
(53-55). While PLD1 and PLD2 contain two HKD motifs, PLD6 only contains one and 
therefore homodimerizes with the catalyticaly active site at the dimer interface (53,55). 
The classical PLD isoforms contain PX and PH lipid-binding domains to associate with 
membranes while PLD6 contains a N-terminal mitochondrial localization signal, which 
also functions as a transmembrane domain (55). PLD6 is anchored in the outer 
mitochondrial membrane and functions as a lipase and endonuclease (53,55). As a lipase, 
it hydrolyzes the mitochondrial specific lipid cardiolipin to produce phosphatidic acid. 
Additionally, PLD6 is an endonuclease involved in maturation of piwi-interacting RNA 
(piRNA) by defining the 5’ end of piRNA and associating with the piwi-interacting 
protein Aubergine (53).  The substrate-binding pocket is positively charged and can 
therefore accommodate negatively charged ssRNA or ssDNA (53,56,57). PLD6 is most 
abundantly expressed in the testes where its involvement in the piRNA pathway is 
important to spermatogenesis (53). This is where PLD6 is most studied and characterized 
and little is known about PLD6 in other tissues.  
 Some of the important cellular functions mitochondria regulate include apoptosis, 
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intracellular calcium signaling, and lipid synthesis and transport (55,58,59). Mitochondria 
are a dynamic organelle system, constantly undergoing fusion and fission. In this manner, 
mitochondrial size, shape, and number adjust to cellular demands, which is important for 
human health (55). Furthermore, mitochondrial fusion and fission allows exchange of 
internal RNAs, proteins, and lipids to aid in homogenizing mitochondrial content 
throughout the cell (60). A disruption in mitochondrial dynamics can lead to pathologies 
such as excess apoptosis (55), neurodegenerative disorders such as Charcot-Marie-Tooth 
subtype 2A (61), dominant optic atrophy (62), metabolic disorders (63), and cardiac 
failure (64,65). Elongated mitochondria are difficult for autophagosomes to engulf and 
therefore cells with many enlarged mitochondria experience severly defective mitophagy 
and the accumulation of damaged mitochondria (66-68). Experiments overexpressing 
PLD6 resulted in elongated mitochondria (54) while silencing PLD6 resulted in 
mitochondrial fragmentation (54,69). Furthermore, these studies implicated the catalytic 
activity of PLD6 in their findings. On the mitochondrial surface, PLD6 converts 
cardiolipin (CL) to phosphatidic acid (PA). In mitochondrial fission, the cytosolic protein 
dynamin-related protein 1 (Drp1) is recruited to the mitochondrial membrane where it 
oligomerizes and its GTPase activity leads to the constriction of the mitochondrial 
membrane (67,70,71). Drp1 can bind to the polar head of PA and this association inhibits 
the GTPase activity of Drp1 (67). In addition, Drp1 binds PLD6, which enriches the PA 
content in the microenvironment of mitochondrial fission machinery (67). PA is 
converted to DAG by the phosphatase Lipin 1 (72). PA recruits Lipin 1 to the 
mitochondrial membrane and thus the occurrence of several fussion events is followed by 
a fission event (68). A study in Drosophila showed that not only did PLD6 
overexpression oppose mitochondrial fragmentation, this opposition reduced necessary 
apoptosis during embryogenesis (73). Furthermore, mitochondrial fission is an important 
upstream event of cytochrome c release during apoptosis. Figure 3B illustrates the lipase 
activity of PLD6 in mitochondria.  
 
Mitochondria and Cancer Beginning with Dr. Warburg’s pivotal proposal in 1956, 
mitochondria have been of interest in studies of cancer initiation and disease progression. 
Dr. Warburg believed that the primary cause of all cancers was derived from a shift of 
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energy production from oxidative phosphorylation to glycolysis due to dysfunctional 
mitochondrial activity (74). It has since been demonstrated that oxidative 
phosphorylation (OXPHOS) efficiency remains unchanged in cancer cells (75-77), but it 
is true that cancer cells rely more heavily on glycolysis than do normal cells (75,78,79). 
Normal cells derive approximately 70% of their ATP from oxidative phosphorylation in 
the inner mitochondrial membrane and the remaining 30% from the less efficient 
glycolysis (75,80). This switch is associated with worse clinical outcome for cancer 
patients (81). Glycolysis is much less efficient, producing 2 ATP molecules per cycle, 
while OXPHOS generates 32 ATP, however, glycolysis is quicker and better for the 
hypoxic environment usually associated with a rapidly proliferating tumor (81-83).  
Of course, mitochondria have vital functions in the cell namely bioenergetic and 
apoptosis-related pathways, both of which are important to cancer progression. 
Mitochondria are well known for housing the machinery for oxidative phosphorylation, 
the major ATP producing pathway with cells. However, another bioenergetic pathway is 
that of glutamine metabolism with the mitochondrial enzyme glutaminase (75). 
Moreover, glutamine metabolism is important in highly proliferative cancer cells, with 
cancer cells being seemingly “addicted” to glutamine (84). Glutamine is an important 
amino acid metabolite for several cellular pathways including oxidative metabilism and 
ATP generation, serving as another energy source. In cancer cells, glutamine becomes in 
high demand (85,86) and glutamine metabolism falls under the regulation of both tumor 
suppressors and oncogenes (87,88).  
Mitochondria are critical to the intrinsic apoptosis pathway and cancer cells gain 
the ability to avoid apoptosis. Recently, mitochondria have been investigated as potential 
therapeutic targets in the treatment of various cancers. For example, Skrtic et al. showed 
that inhibiting mitochondrial translation had promising results in treating acute myeloid 
leukemia (89).  However, other studies have reported mixed results in the success of 
targeting mitochondria in cancer treatment, suggesting the complex nature of 
mitochondrial function in cancer and context-dependent functions (90-93).   
 
MicroRNA MicroRNA (miRNA, miR) are a subset of non-coding RNA molecules 
that are short RNA molecules, approximately 19-24 nucleotides in length (94-96). 
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MicroRNA precursors undergo several steps of maturation. Primary miRNA (pri-
miRNA) transcripts are synthesized by RNA Polymerase II and contain a stem loop 
structure. While still in the nucleus, pri-miRNAs are cleaved into precursor miRNA (pre-
miRNA) by the RNAse III Drosha and its coenzyme DGCR8. Pre-miRNAs are 
subsequently exported from the nucleus by exportin 5. In the cytoplasm, pre-miRNAs are 
further cleaved to double-stranded mature miRNA duplex by another RNAse III, Dicer 
and its coenzyme TRBP (97-100). Mature miRNA duplexes in the cytoplasm associate 
with Argonaute 2 (Ago2) protein and the RNA Induced Silencing Complex (RISC), 
causing one miRNA strand to dissociate from the complex. As part of RISC, miRNA can 
associate with target messenger RNA (mRNA), usually at the 3’ untranslated region 
(3’UTR), as a loosely conserved compliment to the mRNA sequence. This association 
with mRNA inhibits protein translation either by inhibiting ribosomal function or by 
inducing mRNA degradation (97-99). A schematic of miRNA function is depicted in 
Figure 4. Because of the poor conservation between miRNA and mRNA binding, one 
miRNA can target multiple mRNA and one mRNA can be regulated by multiple miRNA. 
MicroRNA are widely becoming recognized as essential players in proteome regulation 
in development, health, and disease states (97-99). 
 MicroRNA involvement in cancer was first discovered in 2005. Subsequently, 
dysregulation of miRNAs has been documented in almost all types of human cancer. 
Additionally, specific cancers have unique signatures of altered miRNA profiles (101-
103). One reason for this is that miRNAs are often located in genomic regions that are 
deleted, amplified, epigenetically modified, et cetera in cancer and can, therefore, act as 
tumor suppressors or oncogenes (104). In fact, several animal studies demonstrated that 
alterations in miRNA expression is sufficient to induce neoplasia in cells (105-107). 
MicroRNAs can also function as both activators and suppressors of tumor metastasis 
(108-111). Furthermore, individual miRNAs has been shown to serve as both an 
oncogene or tumor suppressor depending on the cell type (101,112,113). MicroRNAs can 
function cooperatively to achieve a more universal affect on cancer (114,115). This 
makes therapeutic targeting single specific miRNA molecules more challenging and 
suggests therapeutically targeting the broader effects would be a more promising avenue. 
Additionally, differing expression patterns of microRNA has been documented in cases 
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of drug resistant tumors, suggesting miRNA expression and regulation could be key to 
understanding the complex nature of chemotherapy resistance (5,116). This further 
supports the exploration of miRNAs as therapeutic targets.  
 
Overall, PLD1 and PLD2 have been shown to be upregulated in breast cancer and 
their increased expression and activity was correlated with worse prognosis. Additionally, 
much of the human proteome is regulated by miRNA, which are also frequently 
dysregulated in cancer. Finally, studies on the mitochondrial PLD isoform, PLD6, 
suggest it may play a role in breast cancer. Thus, I hypothesize that the dysregulation 
of PLD isoforms in breast cancer promotes cell invasion.  
  
The objectives of this proposal were attained by pursing the following specific 
aims: 
 
Specific Aim 1: To investigate the molecular regulation of classical PLD isoforms by 
microRNAs in breast cancer cell invasion.  
Specific Aim 2: To study the molecular regulation of classical PLD isoforms by 
microRNAs in breast cancer cells subjected to nutrient starvation.  
Specific Aim 3: To determine the effect of upregulated PLD6 in breast cancer cells on 
cell invasion. 
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Figure 1. Human breast cell lines. HMEC (Human Mammary Epithelial Cells) are non-
cancerous breast cells, characterized by their epithelial cell morphology and propensity to 
grow in clusters. MCF-7 cells are a low invasive ductal breast cancer cell line that retains 
some degree of cuboidal morphology and are characterized as estrogen receptor (ER) 
positive. MDA-MB-231 cells represent a highly invasive ductal breast carcinoma cell line 
that have lost epithelial morphology and have a spindle-like morphology. Additionally, 
MDA-MB-231 cells are classified as triple negative and therefore do not express the 
estrogen, progesterone, or HER2 receptors. Images were taken at 40X magnification.  
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Figure 2. Characteristics of the mammalian phospholipase D isoforms. All PLD isoforms 
contain at least one characteristic HKD catalytic motif. The classical PLD isoforms are 
PLD1 and PLD2 and are the most well characterized isoforms. They have lipase activity 
hydrolyzing phosphatidyl choline to free choline and phosphatidic acid. Their PH and PX 
domains anchor PLD to the membrane via interaction with lipids. PLD3 and PLD4 are 
transmembrane proteins localizing to the ER and Golgi respectively. PLD6, also termed 
mitoPLD, is the smallest isoform and localizes to the outer mitochondrial membrane. It 
dimerizes and functions as a lipase, hydrolyzing cardiolipin to phosphatidic acid, and also 
functions as an endonuclease in the maturation of piRNA. 
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Figure 3. Chemical reaction of PLD lipase activity. (A) The lipase activity PLD1 and 
PLD2 involves hydrolysis of the membrane lipid phosphatidyl choline into free choline 
and phosphatidic acid. The small box indicates the lipid bonds cleaved by several 
phospholipases. (B) PLD6 localizes to the outer mitochondrial membrane where it 
hydrolizes cardiolipin (CL) to produce phosphatidic acid (PA). PA can be 
dephosphorylated by Lipin 1 to produce diacyl glycerol (DAG). The chemical structure 
of CL is also shown. Panel A was adapted from a figure published by Gomez-
Cambronero (117) and used with author permission.  
 
 
13	
 
 
 
 
 
 
 
 
 
 
Figure 4. Mechanism of action of microRNA. After several nuclear and cytoplasmic 
processing steps, mature microRNA associate with Ago2 protein in the RISC (RNA 
Induced Silencing Complex). The entire complex binds to target mRNA via 
complementarity to the microRNA seed sequence. Once bound, the RISC either inhibits 
protein translation of the mRNA by interfering with ribosomal function or promoting the 
degredation of the mRNA.  
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CHAPTER 2. MATERIALS AND METHODS 
 
 Reagents. miRNA mimics predicted to target PLD1 or PLD2 mRNA were Dharmacon 
products purchased from GE Healthcare. The putative PLD1 mRNA-targeting miRNA 
was 182–5p (TargetScan Human accession number MIMAT0000259). The miRNAs 
predicted to target PLD2 mRNA were 203a, 3619–5p, 887–5p (accession numbers 
MIMAT0000264, MIMAT0017999, and MIMAT0004951 respectively). For specific 
experiments (as indicated in the text and figures) miRNA plasmids were used that also 
contained a GFP coding sequence. miExpress Precursor miRNA Expression Clones were 
from GeneCopoeia (Rockville, MD) and include these catalogue numbers: HmiR0249-
M04-B, HmiR0957-MR04-B, and HmiR0512-MR04-B, which are specific for these 
miRNAs: hsa-mir-203, hsa-mir-3619, and hsa-mir-887, respectively. Additionally, one 
Precursor miRNA Expression Clone for PLD1 was from GeneCopoeia, that of hsa-mir-
182 (catalogue# HmiR0115). Transit2020 transfection reagent was from Mirus (Houston, 
TX). Chemical inhibitors of PLD lipase activity, FIPI and NFOT, were purchased from 
Cayman Chemical (Ann Arbor, MI).  
 
Cell Culture. MDA-MB-231, MCF-7, BT-474, and BT549 human breast cancer cells 
and MCF-10A transformed human breast cells were obtained from ATCC (Manassas, 
VA). Primary human mammary epithelial cells (HMEC) were obtained from Cell 
Applications Inc. (San Diego, CA). MCF-7 and MDAMB-231 cells were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% (vol/vol) fetal 
calf serum (FCS). BT-474 cells were cultured in Hybri-Care medium (ATCC) 
supplementedwith 1.5 g/liter NaHCO3 and 10% fetal bovine serum (FBS). BT-549 cells 
were cultured in RPMI 1640 medium (ATCC) supplemented with 0.023U/ml insulin and 
10% FBS. HMEC and MCF-10A cells were cultured in mammary epithelial cell growth 
medium including bovine pituitary extract (BPE), human epidermal growth factor 
(hEGF), hydrocortisone, GA-1000, and insulin. HMEC were cultured on collagen-coated 
flasks. Cells were maintained at 37°C in an incubator with a humidified atmosphere of 
5% CO2. 
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Cell Starvation. To starve cells, medium was aspirated from cells, which were then 
washed 2 times with phosphate-buffered saline (PBS) and incubated in cell starvation 
medium (DMEM, 0.1% bovine serum albumin [BSA]) for several lengths of time as 
indicated in the legends of the figures. 
 
Transfection of Cells. Cells were seeded in 6-well plates with an equal number of cells 
per well and were then allowed to grow for 12 to 24 h prior to transfection. Plasmid 
transfection reaction mixtures included 1 to 2 µg of DNA plasmid and 1 µg DNA per 2-
µl volume of Transit2020 transfection reagent. Mimic transfection reaction mixtures 
included 100 nM the appropriate miRNA mimic and the appropriate volume of 
DharmaFECT2 transfection reagent based on the cell line and number of cells seeded as 
recommended by the manufacturer. Transfection reactions were added to complete media 
and incubated with cells overnight. Media was replaced and samples were trypsanized 
and collected 36 to 48 h after initial transfection. 
 
PLD Activity Assays.  Samples were processed for PLD lipase activity in PC8 liposomes 
and n-[3H]butanol beginning with the addition of the following (final concentrations): 3.5 
mM PC8 phospholipid, 45 mM HEPES (pH 7.8), and 1.0 uCi n-[3H]butanol in a 
liposome form. Samples were incubated for 20 min at 30°C with continuous shaking. 
Addition of 0.3 ml ice-cold chloroform-methanol (1:2) stopped the reactions. Lipids were 
then isolated and resolved by thin-layer chromatography. The amount of 
[3H]phosphatidylbutanol-di- 16:0 ([3H]Pbut) that co-migrated with PBut standards was 
measured by scintillation spectrometry.  
 
Western blotting. Cells were transfected with expression plasmids as described in the 
figure legends, and examined after 2 days. Cells were lysed in special lysis buffer (SLB; 
consisting of 5 mM HEPES, 1mM leupeptin, 768 nM aprotinin, 100 uM sodium 
orthovanadate, and 0.4% Triton X-100). After sonication, aliquots of the supernatant 
were resolved by SDS-PAGE, transferred to a polyvinylidenedifluoride (PVDF) 
membrane, followed by immunoblot analysis with IgG antibodies as described in figure 
legends, and visualized using enhanced chemiluminescence (ECL) reagents. 
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Subcellular Fractionation. Cells were trypsanized and pelleted at 200 x g for 7 min. 
Pellets were resuspended in 400 µl of Buffer A (250 mM sucrose, 50 mM Tris-HCl pH 
7.4, 5 mM MgCl2, and 1% protease inhibitors leupeptin and aprotinin). Samples were 
homogenized on ice and homegenates were incubated on ice for 30 min. Samples were 
vortexed at max speed for 15 sec and subsequently pelleted at 800 x g for 15 min. The 
resulting supernatant (Sc) contained the cytoplasmic fraction and was saved for later use. 
The pellet contained the nuclear fraction and was resuspended in 400 µl of Buffer A. The 
nuclear fraction was then vortexed at max speed for 15 sec and then centrifuged at 500 x 
g for 15 min. The supernatant was discarded and the pellet containing the nuclear fraction 
was washed twice with 400 µl of Buffer A, pelleting at 500 x g for 15 min. The final 
wash was pelleted at 1000 x g for 15 min. The supernatant was discarded and the pellet 
was resuspended in Buffer B (20 mM HEPES pH 7.9, 1.5 mM MgCl2, 0.5 M NaCl, 0.2 
mM EDTA, 20% glycerol, 1% Triton-X-100, and 1% protease inhibitors leupeptin and 
aprotinin). The nuclear fraction was vortexed at max speed for 15 sec and incubated on 
ice for 30 min. Nuclei were lysed with sonication and centrifuged at 9000 x g for 30 min. 
The supernatant was the final nuclear fraction. The cytoplasmic fraction (Sc) was further 
processed to separate mitochondrial fraction. Sc is centrifuged at 800 x g for 10 min. The 
pellet was discarded and the supernatant was further centrifuged at 11,000 x g for 10 min. 
Supernatant contains cytosolic fraction and was transferred to a new tube. The pellet (PM) 
contains the mitochondrial fraction and was kept on ice. The cytosolic fraction was 
precipitated in cold 100% acetone at -20oC for at least 1 hr. The fraction was then 
centrifuged at 12,000 x g for 5 min. The supernatant was discarded and the pellet was 
resuspended in Buffer A and was labeled final cytosolic fraction. The mitochondrial 
pellet (PM) was resuspended in Buffer A and centrifuged at 11,000 x g for 10 min. The 
supernatant was discarded and the mitochondrial pellet was resuspended in Buffer C (50 
mM Tris-HCl pH 6.8, 1 mM EDTA, 0.5% Triton-X-100, and 1% protease inhibitors 
leupeptin and aprotinin). The mitochondria were lysed by sonication and this was labeled 
the final mitochondrial fraction. This protocol was adapted from (118). 
 
Gene expression measurement by qRT-PCR. Total RNA was isolated from cells with 
the RNeasy minikit according to the manufacturer’s protocol (Qiagen, Valencia, CA). 
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RNA concentrations were determined using a NanoDrop, and samples were diluted to 50 
ng/µl RNA. Reverse transcription was performed with 2 µg RNA, 210 ng random 
hexamers, 500 µM deoxynucleotide triphosphates (dNTPs), 84 units RNaseOUT, and 
210 units of Superscript II reverse transcriptase, and the mixture was incubated at 42°C 
for 55 min. Quantitative real-time reverse transcription-PCR (qRT-PCR) assays were run 
with 100 ng total input RNA, 2µl of PLD1 gene expression assay mixture (6-
carboxyfluorescein FAM labeled), or 2 µl of the PLD2 gene expression assay mixture 
(FAM labeled) or with the housekeeping gene (ß-actin) (FAM labeled), with the final 
concentrations being 200 pmol and 400 pmol for the primers and probe, respectively. 
Primers and fluorescent probes were synthesized by ThermoFisher Scientific. qRT-PCR 
conditions for the Stratagene Cycler were 95°C for 3 min and then 50 cycles of the next 3 
steps, i.e., 30 s at 95°C, 1 min at 60°C, and then 1 min at 72°C. The cycle threshold (CT) 
values were arbitrarily chosen from the linear part of the PCR amplification curve, where 
an increase in fluorescence can be detected at >10 standard errors of the means (SEM) 
above the background signal. ΔCT was calculated as follows: ΔCT  = avg PLD CT   
avg housekeeping CT (where avg is average), and the gene fold increase expression was 
calculated as 2-ΔΔCT = 2(experimental condition ΔCT - control ΔCT). 
 
Quantitative reverse transcription-PCR for microRNAs. Cells that were transfected 
with the PLD miExpress Precursor miRNA expression clones were used for RNA lysates 
48 h post-transfection using the TaqMan microRNA Cells-to-CT kit according to the 
manufacturer’s protocol (catalog no. 4391848; Life Technologies). RNA concentrations 
were determined using a NanoDrop, and samples were normalized to ~66 ng/µl RNA. 
Reverse transcription was performed in a 15-µl reaction volume with 1 µg of RNA, 1.5 
µl 10X buffer, 1 mM dNTPs, 3.8 units of RNase inhibitor, and 1 µl of Multiscribe reverse 
transcriptase, and the mixture was incubated in one cycle at 16°C for 30 min, 42°C for 30 
min, and then 85°C for 5 min. Quantitative RT-PCRs were run in a 20-µl reaction volume 
using 10 µl TaqMan master mix, ~88 ng of total input RNA, 1 µl of the relevant 
microRNA gene expression assay (FAM labeled) multiplexed with the housekeeping 
gene (U6 FAM labeled). TaqMan miRNA primers and fluorescent probes were from Life 
Technologies. Quantitative PCR conditions for the Stratagene Cycler were 95°C for 10 
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min and then 40 cycles of the next 3 steps, i.e., 15 s at 95°C, 1 min at 55°C, and then 30 s 
at 72°C. The CT values were chosen from the linear part of the PCR amplification curve, 
where an increase in fluorescence can be detected at >10 standard errors (SE) above the 
background signal. ΔCT was calculated as follows: ΔCT =avg PLD CT - avg 
housekeeping CT. The gene expression fold change was calculated as 2-ΔΔCT = 2 (experimental 
condition 
Δ
CT - control 
Δ
CT).  
 
Immunofluorescence microscopy. Cells were fixed onto coverslips using 4% 
paraformaldehyde in PBS for 10 min at room temperature, permeabilized with 0.1% 
Triton X-100 in PBS for 10 min at room temperature, and then incubated in IF blocking 
buffer (10% FCS–0.1% Triton X-100 in PBS) for up to 4 h at room temperature. Primary 
antibodies, as described in figure legends were diluted (1:200) in IF blocking buffer 
overnight at 40C. Cells were incubated with a 1:2000 dilution of secondary antibody: 
donkey anti-rabbit or donkey anti-mouse IgG antibody conjugated with tetramethyl 
rhodamine isothiocyanate (TRITC) or fluorescine (FITC) for 1 h at room temperature. 
Nuclei were stained using a 1µg/ml dilution of 4,6-diamidino-2-phenylindole (DAPI) in 
PBS for 5 min at room temperature. Coverslips were mounted onto glass microscope 
slides using VectaShield mounting medium, and cells were visualized using a Nikon 50 
Eclipse epifluorescence microscope or an Olympus FV1000 confocal microscope. 
 
Luciferase reporter assay. Luciferase reporter assays were performed using the 
LightSwitch luciferase assay kit from ActiveMotif (catalog no.32031). The reporter 
vectors contain a 3’UTR region and a downstream RenSP luciferase region. Cells were 
co-transfected as previously described with either a miRNA mimic or plasmid and a 
LightSwitch 3’UTR positive control vector or PLD2 3’UTR vector in a 96-well plate. 
After 36 h, Light-Switch luciferase assay reagent was added to the wells, and the signal 
was read on a luminometer. The signal knockdown from the control was normalized to a 
negative-control mimic. 
 
Cell invasion assay. MDA-MB-231 human breast cancer cells were serum starved for 2 
h and resuspended at a concentration of 1.5 x 106 cells/ml in chemotaxis buffer (DMEM 
19	
+ 0.5% bovine serum albumin). Next, 3 x 105 cells were applied to the upper chambers of 
8 µm pre-coated PET Matrigel inserts (Corning Life Sciences) with a 6.5-mm-diameter 
membrane, and cells were allowed to invade for 6 h at 37°C in a humidified 5%CO2 cell 
culture incubator. The final concentration of chemoattractant used was 0 or 30 nM EGF 
in 500 µl of chemotaxis buffer placed in the lower wells of 24-well plates. Matrigel was 
scraped from the insert and cells were then stained for 1 h with hematoxylin. Six separate 
fields of cells were counted for each invasion assay, and results were expressed in terms 
of total number of invading cells. 
 
 Identifying PLD-targeting miRNAs. Knowing the 3’UTR sequences of both PLD 
isoforms, PLD1 and PLD2, we found five putative miRNAs that align with specific 
regions by using the TargetScan-Human bioinformatics analysis 
(http://www.targetscan.org/vert_71/) (119). Additionally, we found that the predicted 
binding site of these five microRNA to PLD mRNA is widely conserved among several 
mammalian species as shown in Table 1. We used several bioinformatic algorithms to 
determine the favorability of miRNA:mRNA binding pairs, which are also reported in 
Table 2. First we calculated the Gibbs free energy of the miRNA seed sequence:mRNA 
binding using mfold web server (The RNA Institute, University At Albany; 
http://unafold.rna.albany.edu/?q=mfold). Second, the mirSVR score (120) as obtained 
from the miRanda database (http://www.microrna.org/microrna/home.do) was reported. 
Finally, we reported the weighted context score as reported by TargetScanHuman and 
calculated according to Agarwal et al (119). The mirSVR score and weighted context 
score represent different algorithms in miRNA binding prediction that incorporate 
multiple miRNA:mRNA binding factors. In all, negative scores represent favorable 
binding, with greater favorability with increased score magnitude. DNA plasmids from 
GeneCopoeia were derived with the relevant miRNAs sequences cloned in or a 
scrambled negative control clone (catalog nos. HmiR0249-MR04-B, HmiR05120MR0–
04-B, Hmi-R0957-MR04-B, and CmiR0001-MR04-B) as well as RNA mimics from GE 
Healthcare-Dharmacon (catalog nos. C-300605-05-0002, C-300557-07-0002, C-300562-
03-0002, C-301245-01-0002, C-301515-00-0002, or CN-001000-01-05). Additionally, 
luciferase reporter plasmids were generated by LightSwitch (Active Motif) with the 
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3’UTR sequence of PLD2 downstream to a RenSP optimized luciferase gene with a 
constitutive promoter on a pLightSwitch_3UTR backbone plasmid.  
 
Xenotransplant of SCID mice and metastatic breast cancer models. Mouse studies 
were conducted as described by Henkels et al (28). Briefly, 4-6 x 106 cells were injected 
into the left mammary fat pad of SCID mice under isoflurane anesthesia. Tumors were 
allowed to grow for approximately 4 weeks at which time mice were humanely 
euthanized. The primary breast tumor and lung metastases were surgically excised. 
Tumors serial sections were fixed onto glass slides. Samples were stained with 
hematoxylin and eosin or processed for immunofluorescence staining.  Stably transfected 
cell lines used in the mouse study were generated via lentiviral transfection as described 
in (28). Lentiviral transfection of MDA-MB-231 cells with pLenti vector (pKLO-
shControl or pKLO-shPLD2 Sigma cat no. NM_002663) was conducted as described by 
Henkels et al (121). 
 
Statistical analysis. The data presented in the figures as bars are means + SEM (standard 
deviation/√(n-1), where n = sample size). Experiments were performed in duplicates for 
at least 3 independent experiments. The difference between means was assessed by the 
student t-test, calculated using GraphPad Prism 7.0 software (GraphPad Software Inc., La 
Jolla, CA). A probability (P) of <0.05 indicates a significant difference. 
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CHAPTER 3. AIM 1. 
 
Specific Aim 1: To investigate the molecular regulation of classical PLD isoforms by 
microRNA in breast cancer cell invasion.  
 
Rationale  
The classical isoforms of PLD, PLD1 and PLD2, are overexpressed in various 
cancers and aid tumorigenesis and metastasis. Our lab and others have demonstrated 
pharmacologic inhibition of classical PLD isoforms was advantageous in reducing tumor 
size and metastases in breast cancer mouse models (28,122). Current small molecule 
inhibitors are profusely hydrophobic, difficult to solubilize, and exert deleterious side 
effects. Thus, alternative regulation of PLD, specifically microRNA regulation, is of 
interest due to the growing interest in investigating miRNAs as therapeutic agents. The 
post-transcriptional regulation of classical PLD molecules is widely unexplored. 
Although it has been previously reported that miR-203 inhibits the proliferation and 
invasion of U251 glioblastoma cells by directly targeting PLD2 (22), this study did not 
provide insights into the molecular mechanisms of how this was accomplished. Likewise, 
it is unlikely that only one miRNA will be enough to down regulate PLD, as it appears to 
be common biologocially that several miRNAs cooperate to impede translation of a 
particular protein.  
 
Experimental Design  
In the first subaim, Western blot and qRT-PCR were used to determine the protein 
and mRNA levels of PLD1 and PLD2 in the breast cell lines of interest. Additionally, an 
in vitro lipase activity assay was used to assess the enzymatic activity of PLD1 and PLD2 
in the cell lines. Matrigel invasion assays were conducted to confirm the invasion 
phenotype of the cell lines as well as compare invasion capability in the presence or 
absence of PLD1 or PLD2 overexpression.  
In the second subaim, miRNA predicted to target either PLD1 or PLD2 mRNA 
were identified using bioinformatic analysis websites including TargetScan Human and 
miRNA.org. Then, the miRNA expression levels in our cell lines was determined and  
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miRNA expression inversely correlated with PLD protein expression. To determine if the 
miRNA selected can regulate PLD expression, PLD protein expression was measured in 
breast cancer cells overexpressing miRNA by Western blot and immunofluorescence. 
PLD lipase activity was also assessed in the presence of overexpressed miRNA. 
Furthermore, PLD activity was measured in the presence of combinations of miRNA. 
Finally, miRNA targeting of PLD was detected using a luciferase reporter assay with a 
reporter plasmid containing the PLD 3’UTR that, if targeted by the miRNA, will repress 
the translation of luciferase.  
Finally in the third subaim, the effect of exogenous miRNA on cell invasion in 
both cancer cell lines was evaluated. PLD and miRNA plasmids were co-overexpressed 
to observe if miRNA can reverse the positive effect of PLD upregulation on cell invasion. 
Additionally, because highly invasive breast cancer cells have presumably undergone 
EMT, the role of EMT effectors on miRNA expression in high and low invasive cell lines 
were investigated.  
 
Subaim 1A: To characterize PLD1 and PLD2 expression and signaling in breast 
cancer cell lines.  
 
Results 
PLD1 and PLD2 expression was evaluated in several breast cancer cell lines to 
compare to previously reported results as well as establish a cell line model to further 
explore miRNA regulation. Endogenous protein expressions of both isoforms of 
“classical” PLD (PLD1 and PLD2) were elevated in MCF-7 (low-invasive luminal) and 
MDA-MB-231 or BT-549 (high-invasive, epidermal growth factor receptor [EGFR]-
high) cancer cells compared to normal MCF-10A cells or HMEC (Figure 5). 
Additionally, relative endogenous pld1 and pld2 gene expression levels were increased in 
the four cancer cell lines tested (MCF-7, MDA-MB-231, BT-474, and BT-549) compared 
to the two normal breast cell lines (MCF-10A and HMEC) (Figure 6), with MDA-MB-
231 and BT-549 having the highest (2.5-fold over controls) basal levels. This correlates 
with previously reported increases in PLD1 and PLD2 mRNA and protein expression in 
invasive breast cancer (28,123). As shown in Figure 7, basal lipase activity was elevated 
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in MDA-MB-231 and BT-474 cell lines compared to HMEC, although not in the MCF-7 
cell line and only marginally in the BT-549 cell line. Taken together, these data indicate 
that high-invasive breast cancer cells have higher levels of PLD gene and protein 
expression, which correlated to increased PLD activity compared to that of the respective 
controls. Of note, both PLD1 and PLD2 mRNA and protein are lower in BT-474 cells 
than BT-549 cells (Figures 5-6). However, the PLD lipase activity in these cell lines is 
similar (Figure 7). One possible explanation is that a higher percentage of PLD protein 
found in BT-474 cells is phosphorylated and therefore active, when compared to BT-549 
cells. A Western blot using an antibody specific for the phosphorylated form of PLD 
would aid in answering this question. Further, a consistent pattern of PLD expression and 
activity was more apparent when comparing MCF-7 and MDA-MB-231 cells as low and 
highly aggressive breast cancer cells respectively. For instance, MDA-MB-231 cells 
showed elevated protein and gene expression of both isoforms as well as elevated lipase 
activity when compared to MCF-7 cells. In contrast, the highly aggressive BT-549 cells 
had less measurable PLD lipase activity than the less aggressive BT-474 cells. Similarily, 
both BT cell lines showed similar levels of PLD2 protein expression. Thus, I chose to 
continue investigating PLD in MCF-7 and MDA-MB-231 cells for low and highly 
aggressive breast cancer cell lines respectively. Similar results in the non-cancerous 
HMEC and MCF-10A cell lines were observed and both were used as control cell lines.  
Next, it was investigated if PLD1 and PLD2 protein expression correlated with 
cell invasiveness. To confirm the reported invasiveness of MCF-7 or MDA-MB-231 a 
Matrigel-based cell invasion assay was performed, using EGF (30 nM) as a 
chemoattractant. As shown in Figure 8, both low-invasive MCF-7 and high-invasive 
MDA-MB-231 breast cancer cells increasingly migrated through the Matrigel matrix in 
response to EGF as a function of time, whereas control HMEC cells did not invade to any 
great extent during the same timeframe. The increased cell invasion of MDA-MB-231 
cells relative to MCF-7 and HMEC cells is consistent with reported literature and 
additionally, correlates with increased PLD expression and activity under basal 
conditions. Figure 8B shows photomicrographs of representative fields for invaded cells 
(after 6 h) in Matrigel membranes. EGF was chosen as a chemoattractant because EGF 
signaling activates PLD (124) and further EGF promotes cell migration (125). The levels 
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of pld2 gene expression in three breast cell lines were evaluated after increasing time of 
incubation with epidermal growth factor (EGF). Figure 9A documents significantly 
increased PLD gene expression in the highly aggressive MDA-MB-231 cells compared 
with HMEC cells after EGF stimulation, suggesting a role for PLD in breast cancer cell 
invasion. Further, little increase in pld2 gene expression was observed in response to 
EGF treatment in MCF-7 cells. In a tandem experiment, PLD lipase activity was 
measured in response to EGF treatment in the same three cell lines. Again, the largest 
increase in PLD activity was observed in MDA-MB-231 cells. However, there was a 
significant increase in PLD lipase activity observed in MCF-7 cells as well. This 
indicates that while EGF treatment doesn’t necessecarily increase pld2 gene expression, 
there is an increase of PLD enzymatic activity in response to EGF. This is an important 
finding when considering the increased cell invasion observed in MCF-7 cells in response 
to EGF. MCF-7 cells express less copies of EGFR when compared to MDA-MB-231 
cells (126). However, the observed increase in PLD lipase activity in both cell lines likely 
contributes to the increased cell invasion in the presence of EGF.  
Small molecule inhibitors were used to further investigate PLD lipase activity in 
cell invasion. The two inhibitors used were FIPI and NFOT, and their characteristics are 
summarized in Table 1. FIPI is a dual PLD1 and PLD2 inhibitor, while NFOT is a PLD2-
specific inhibitor. Wild type and PLD2-overexpressing MDA-MB-231 cells were treated 
with two concentrations of either FIPI or NFOT and cell invasion eas measured (Figure 
10A). There was a significant increase in cell invasion in the presence of overexpressed 
PLD2, which was subsequently negated by treatment with either FIPI or NFOT. Wild 
type MDA-MB-231 cells also showed diminished cell invasion when treated with FIPI or 
NFOT. This experiment strongly suggests PLD, particularly PLD2, promotes breast 
cancer cell invasion. Figure 10B demonstrates that FIPI and NFOT are able to inhibit 
lipase activity of both endogenous and transiently overexpressed PLD2 in MDA-MB-231 
cells, with increasing inhibitor concentrations yielding less PLD lipase activity. Data for 
Figure 10 were graciously provided by Ramya Ganesan and Madhu Mahankali.  
In this subaim, elevated expression of PLD1 and PLD2 gene and protein as well 
as increased lipase activity was detected in invasive breast cancer cell lines. Furthermore, 
EGF signaling increased PLD activity, which correlated with increased cell invasion 
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when EGF was used as a chemoattractant. Finally, chemical inhibition of PLD activity 
reduced breast cancer cell invasion in a Matrigel-based assay.  
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Figure 5. PLD1 and PLD2 protein expression in multiple breast cell lines. Western blot 
analysis of endogenous PLD1 and PLD2 protein expression was detected in several 
cancerous and non-cancerous breast cell lines. MCF-10A and HMEC cell lines are non-
cancerous human breast cells. MCF7 and BT-474 are low invasive human breast cancer 
cell lines. MDA-MB-231 and BT-549 are highly invasive human breast cancer cell lines. 
The Western blot shows an increase in both PLD1 and PLD2 protein levels in breast 
cancer cell lines when compared to non-cancerous breast epithelial cells. β-actin was 
used as a loading control.  
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Figure 6. pld1 and pld2 transcript levels in multiple breast cell lines. qRT-PCR was used 
to measure pld1 and pld2 mRNA levels, (A) and (B) respectively, in cancerous and non-
cancerous human breast cell lines. MCF-10A and HMEC cell lines are non-cancerous 
human breast cells. MCF7 and BT-474 are low invasive human breast cancer cell lines. 
MDA-MB-231 and BT-549 are highly invasive human breast cancer cell lines. The gene 
expression of both PLD isoforms was increased in cancerous cell lines when compared to 
non-cancerous cells. Expression was normalized to β-actin. A probability (P) of <0.05 
indicates significance and was calculated with the student t-test. (*) denotes a significant 
increase relative to MCF-10A. (#) denotes a significant decrease relative to MCF-10A.  
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Figure 7. Basal PLD enzymatic activity in multiple breast cell lines. PLD lipase activity 
was measured in whole cell lysates of cancerous and non-cancerous human breast cells. 
MCF-10A and HMEC cell lines are non-cancerous human breast cells. MCF7 and BT-
474 are low invasive human breast cancer cell lines. MDA-MB-231 and BT-549 are 
highly invasive human breast cancer cell lines. Because PLD1 and PLD2 perform the 
same enzymatic reaction, this assay does not distinguish between the activity of the 
isoforms and therefore represents total PLD activity. Basal PLD lipase activity was 
elevated in three of the breast cancer cell lines relative to MCF-10A. Bars represent 
dpm/mg protein of the cell lysate (x104). A probability (P) of <0.05 using the student t-
test, indicates significance. (*) denotes a significant increase relative to MCF-10A.  
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Figure 8. Cell invasion of human breast cell lines. Cell invasion was measured using 
Matrigel inserts and 30 nM EGF was used as a chemoattractant. An equal number of cells 
(500,000) per condition were placed in the upper chamber of the insert and allowed to 
invade for 3 or 6 hours. HMEC cells are non-cancerous human breast epithelial cells. 
MCF-7 and MDA-MB-231 cells are human breast cancer cells with low and high 
invasion phenotype respectively. (A) The mean number +S.E.M. of invading cells (x103) 
for each condition. There was no change in HMEC cell invasion up to 6 hours, whereas 
MCF-7 and MDA-MB-231 cells increased in number of cells invading with increasing 
time. Furthermore, more MDA-MB-231 cells than MCF-7 cells invaded under identical 
conditions. A probability (P) of <0.05 indicates significance, as calculated using the 
student t-test. (*) denotes a significant increase relative to 0 hr of each cell line. (B) 
Representative images (20x magnification) of cell invasion for each cell line after 6 hours 
of invasion. Green arrows point at examples of empty pores in the insert membrane. Blue 
arrows indicate examples of stained cells. Cell invasion assays were performed in 
duplicate and 6 fields were counted per insert.  
30	
 
 
Figure 9. Effect of EGF on pld2 gene expression and PLD lipase activity. pld2 gene 
expression (A) and PLD enzymatic activity (B) increases with longer stimulation by EGF 
in MDA-MB-231 cells and MCF-7 cells but not in HMEC cells. These data correlate 
with increased invasion seen in response to EGF as a chemoattractant (Figure 8). In (A), 
all samples are relative to 0 hr HMEC. In (B), 0 hr for each cell line was set as 100%. 
Significance was calculated using the student t-test and a probability (P) of <0.05 
indicates significance and is denoted by (*).  
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Table 1. Chemical inhibitors of PLD lipase activity. This table lists the chemical 
inhibitors of PLD used herein including their IUPAC name, abbreviation, chemical 
structure and PLD isoform specificity. Inhibitors were purchased from Cayman Chemical 
(Ann Arbor, MI).  
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Figure 10. Effect of inhibiting PLD lipase activity on cell invasion. (A) Matrigel cell 
invasion assay was conducted with MDA-MB-231 cells using either Mock conditions or 
transiently overexpressed PLD2 protein. Further, cells were treated with two 
concentrations of either FIPI (dual PLD inhibitor) or NFOT (PLD2 specific inhibitor). 
Overexpression of PLD2 increased cell invasion, which was additionally reduced by 
chemical inhibition or PLD and its subsequent enzymatic activity. A probability (P) of 
<0.05 indicates significance using the student t-test and a significant increase is denoted 
by (*) while a significant decrease is denoted by (#). Significant decreases are relative to 
0 nM treated cells in each transfection condition. (B) PLD activity was measured in the 
presence of increasing concentrations of chemical inhibitors, FIPI (red lines) or NFOT 
(black lines). This assay was conducted in MDA-MB-231 cells either mock treated or 
transiently overexpressing PLD2, the same conditions used for the cell invasion assay in 
panel A. Activity is represented as percent of control activity, where 100% is endogenous 
PLD activity in untreated MDA-MB-231 cells. Data for this figure were provided by 
Ramya Ganesan and Madhu Mahankali.  
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Subaim 1B: To identify microRNA regulation of PLD1 and PLD2 in breast cells. 
 
Results 
As shown in the schematic presented in Figure 11, the human pld2 gene is located 
on human chromosome 17. Knowing the 3’UTR sequences of both PLD1 and PLD2 
mRNA, I found four putative microRNAs that target PLD by using bioinformatics 
software (TargetScanHuman). The 3’UTR of PLD2 mRNA spans 568 bp in which 
potential alignment with miR-203, miR-887, and miR-3619 can be found. Note that there 
are two potential regions of alignment for miR-3619 to the PLD2 3’UTR, whereas the 
remaining miRNAs tested herein (miR-203 and miR-887) have only one region of 
alignment with the PLD2 3’UTR. Additionally, miR-182 targeted PLD1 mRNA. The 
species conservation of the miRNA binding sites and several predivtive scores 
(TargetScan; miRNA.org) are listed in Table 2. ΔG values represent the Gibbs free 
energy of the miRNA-mRNA binding pairs and were calculated using the mform web 
server from the RNA Institute at the University at Albany. The mirSVR and Weighted 
Context ++ Scores were reported on the bioinformatic sites miRNA.org and TargetScan 
respectively. These scores use an algorithm to incorporate the complexity of positive and 
negative influences or factors that determine miRNA-mRNA binding. Some of these 
factors include, the number of complementary nucleotides between the pair, the position 
of the miRNA site within the 3’UTR, the flanking mRNA sequence, and secondary 
mRNA structure (119).  
I hypothesized that if one or several microRNA exist that could impair translation 
of PLD mRNA, it might thereby act as a tumor suppressor miRNA. Using miRNA 
primer/probe sets specific for miR-182, -203, -887, and -3619-5p, the endogenous levels 
of expression of each miRNA were measured in the two different human breast cancer 
cell lines, MCF-7 and MDA-MB-231, relative to the control cell line, HMEC. As shown 
in Figure 12, four miRNAs had decreased endogenous miRNA expression in the highly 
invasive MDA-MB-231 cancer cells compared with the low invasive MCF-7 cells. The 
decreased expression of these miRNA in MDA-MB-231 correlates with the increased 
PLD protein observed in the same cell line. Interestingly, MCF-7 cells did not show a 
significant decrease in expression of these miRNA relative to HMEC cells and further, 
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miR-887 actually increased in expression in MCF-7 cells. This suggests that levels of 
these miRNA vary in specific breast cancer cells, most likely downregulated in highly 
invasive breast cancer cells.  
Next, the potential of these miRNA to bind and inhibit translation of PLD mRNA 
was investigated. MCF-7 and MDA-MB-231 cells were transfected with two methods of 
miRNA delivery. Commercially available miRNA plasmids specific encoding for 
miRNA or commercially available miRNA mimics, the double stranded miRNA 
precursor were used. The miRNA-encoding plasmids also contained the GFP gene, 
separate from the miRNA gene, which can be visualized with fluorescence microscopy. 
Confirmation of successful miRNA-overexpression in MCF-7 and MDA-MB-231 cells is 
shown in Figure 16 via miRNA qRT-PCR.  
To assess the effect of miRNA on PLD, miRNA plasmid DNAs were 
overexpressed in cells for 48 h and then whole cell lysates were prepared that were then 
used for SDS-PAGE and subsequent Western blotting or for PLD enzymatic assays. As 
shown in Figure 13 A-B, there was a decrease in PLD2 protein in the presence of the 
PLD2 mRNA-targeting miRNA in both MCF-7 cells and MDA-MB-231 cells. A more 
potent decrease in PLD2 protein expression was observed in MDA-MB-231 cells. MCF-7 
cells have higher endogenous levels of these miRNA than MDA-MB-231 cells and thus 
further overexpressing the miRNA may not have as large an impact on PLD protein 
expression. Similarily, a decrease in PLD1 protein expression was observed in the 
presence of the PLD1 mRNA-targeting miRNA, miR-182 (Figure 13C). Further, the 
decrease in PLD2 protein was shown to be dose-depdent on the anount of miRNA 
transfected (Figure 13D). Additional confirmation of miRNA-dependent downregulation 
of PLD protein was demonstrated by immunofluorescence microscopy (Figure 14). 
MDA-MB-231 cells were transfected with GFP-tagged miRNA plasmids and probed 
with TRITC-labeled anti-PLD2 (A) or anti-PLD1 (B) antibody. Successfully transfected 
cells produce GFP protein and appear green. Therefore, the expression of PLD protein 
can be observed in individual cells that were successfully transfected. In Figure 14, red-
PLD staining was decreased in miRNA-transfected, green-labeled cells. The Mock 
sample was treated with only the transfection reagent and therefore represents 
endogenous PLD protein expression. An empty vector containing the plasmid backbone 
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and GFP gene only (no miRNA gene) shows no effect on PLD protein expression 
compared to the Mock cells. This suggests the decrease in PLD signal observed was due 
to the overexpression of miRNA in indiviual cells.  
PLD enzymatic activity ws evaluated in the presence of miRNA to investigate the 
physiological relevance of decreased PLD protein level. Overexpression of each of the 
four miRNAs tested significantly reduced PLD lipase activity in the highly invasive 
MDA-MB-231 cells compared with non-invasive/non-cancerous HMEC cells (Figure 
15A). Again, the decrease was less obvious in MCF-7 cells. In the presence of miRNA, 
PLD protein levels were decreased to a larger extent in MDA-MB-231 cells compared to 
MCF-7 cells. Thus, this suggests a larger decrease in PLD protein corresponds to a 
learger decrease in PLD lipase activity. Further, a combination of miRNAs produced the 
maximum effect on enzymatic activity (Fig. 15B), with different pairing exerting varying 
effects on lipase activity. This would be important in determining optimal decrease in 
PLD activity to inhibit cell invasion, for example. Additionally, because one miRNA has 
numerous targets, it would be interesting to explore pathways downregulated by miRNA 
combinations.  
Thus far, the data show a correlation between miRNA overexpression and 
decrease in PLD protein expression but direct targeting of miRNA on PLD mRNA has 
not been established. A LightSwitch reporter plasmid containing the 3’UTR sequence of 
PLD2 downstream to a RenSP luciferase gene and microRNA mimics that putatively 
targeted PLD were cotransfected in breast cancer cells (Figure 17A). The 3’UTR of PLD 
was inserted into the LightSwitch plasmid within the RenSP luciferase gene directly 
upstream of the poly-A encoding region. This creates a fusion transcript mRNA attaching 
the PLD 3’UTR to the luciferase mRNA. Presumably, binding of the miRNA to the PLD 
3’UTR would result in diminished luciferase translation, measurable by a luminometer. 
All three miRNAs tested significantly decreased luciferase signal when cotransfected 
with the reporter plasmid in COS-7 cells compared with mock-transfected or scramble 
mimic cells (Figure 17B). This suggests the miRNAs targeting PLD2 mRNA at the 
3’UTR. A further experiment necessary to confirm miRNA binding would have been to 
mutate the predicted miRNA-binding site on the reporter plasmid and demonstrate the 
subsequent loss of miRNA regulation. Unfortunately, this experiment has not been 
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completed at this time. COS-7 cells are non-cancerous fibroblasts and were used in this 
experiment due to their high transfection efficiency. To help ensure co-transfection of 
both the reporter plasmid and miRNA mimic into the same cells and thus to minimize 
erroneous signal, a cell line with a high transfection efficiency was preferred. The breast 
cancer cell lines are much more difficult to transfect and the non-cancerous breast cells 
are difficult to grow. Because the cotransfection of the luciferase plasmid and miRNA 
mimic creates an artificial system, COS-7 cells are an acceptable alternative to the breast 
cell lines for this assay.  
In this subaim, a set of four miRNA were identified that were predicted to bind to 
either PLD2 or PLD1 mRNA. The expression of these miRNA was decreased in highly 
aggressive breast cancer cells. Further, the exogenous addition of these miRNA decreases 
PLD protein levels and PLD lipase activity in breast cancer cells. A luciferase reporter 
assay suggested the downregulation of PLD protein by miRNA was due to miRNA 
binding to the 3’UTR of PLD mRNA.  
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Species miR-182 miR-203 miR-887 miR-3619 
 3’-…AACGGUU 3’-…GUAAAGU 3’-…GGCAAGU 3’-…GACGACU 
Human 5’-…UUGCCAA… 5’-…CAUUUCA… 5’-…CCGUUCA… 5’-…CUGCUGA… 
Chimp 5’-…UUGCCAA… 5’-…CAUUUCA… 5’-…CCGUUCA… 5’-…CUGCUGA… 
Mouse 5’-…UUGCCAA… 5’-…CAUUUCA… 5’-…UGGUUCA… 5’-…CUGCUGA… 
Rat 5’-…UGCCAAA… 5’-…CAUUUCA… 5’-…CGGUUCA… 5’-…CUGCUGA… 
Pig 5’-…UGCCAAA… 5’-…CGUUUCA… 5’-…CAGUUCA… 5’-…CUGCUAC… 
∆G (Human) -13.60 -11.70 -13.40 -19.00 
mirSVR Score -0.4703 -1.2145 -1.3069 Not Available 
Weighted 
Context ++ 
score 
-0.07 -0.08 -0.66 -0.27 
 
 
Table 2. Conserved sequences of PLD 3’UTR-targeting miRNA. 3’UTR sequences 
aligning with miR-182 represent PLD1 3’UTR, while sequences aligning with miR-203, -
887, and -3619 represent PLD2 3’UTR. miR-3619 has two predicted binding sites on 
PLD2 mRNA and the site better predictive score is listed in this table. MicroRNA 
sequences listed are the seed sequence of each miRNA, which represents the miRNA 
region that associates with mRNA. Species conservation information was taken from 
TargetScanHuman. ΔG values were calculated for the human binding pair of the miRNA 
seed sequence and corresponding PLD mRNA sequence using mform web server 
software (The RNA Institute, University at Albany). mirSVR scores are as reported in the 
miRanda-mirSVR database. A negative score denotes a favorable match with scores < -
1.0 representing the top 7% of predictions. Data for miR-3619–5p were not yet available 
on miRanda-mirSVR at time of publication. Weighted context ++ scores were obtained 
from TargetScanHuman based on the algorithm described Agarwal et al (119). Again, a 
negative score denotes a favorable reaction with greater magnitude indicating higher 
favorability. 
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Figure 11. Predicted binding sites of several miRNA on PLD 3’UTR. This schematic 
depicts the binding sites of the miRNA studied herein, as predicted using bioinformatic 
analysis (TargetScan). There are three miRNA predicted to target PLD2 mRNA (miR-
203, -887, -3619) and one miRNA predicted to target PLD1 (miR-182). Also depicted are 
the nucleotide sequences and positions on the mRNA of the binding pairs. It is of note 
that miR-3619 has two predicted binding sites on PLD2 mRNA.  
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Figure 12. Endogenous expression of mature miRNA in human breast cells. qRT-PCR 
was conducted of specific miRNA from whole cell lysates of three human breast cell 
lines. HMEC cells are non-cancerous human breast epithelial cells. MCF-7 and MDA-
MB-231 cells are low and highly aggressive human breast cancer cell lines, respectively. 
Ct values were normalized to U6 housekeeping gene. All four miRNAs were 
downregulated in MDA-MB-231 cells when compared to MCF-7 cells and all but one 
were downregulated compared to non-cancerous HMEC cells. A probability (P) of <0.05 
using the student t-test, indicates significance and a significant increase relative to HMEC 
is denoted by (*) while a significant decrease relative to HMEC is denoted by (#). 
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Figure 13. Exogenous miRNA reduces PLD protein expression. MicroRNA-encoding 
plasmids were transfected into MCF7 cells (A) or MDA-MB-231 cells (B-D) and PLD 
protein expression was measured by Westerm blot. Three microRNAs, miR-203, -887, 
and -3619 were predicted to regulate PLD2 whereas miR-182 was predicted to target the 
PLD1 isorm. Both PLD1 and PLD2 protein expression was decreased in the presence of 
isoform specific miRNA. Densitometry quantification for panel C is represented under 
the blot. Additionally, panel D shows a dose-dependent effect of exogenous miR-3619 on 
PLD2 protein expression. β-actin was used as a loading control. 
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Figure 14. Immunofluorescence of PLD protein after miRNA transfection. MDA-MB-
231 cells were transfected with GFP-tagged miRNA-encoding plasmids. Subsequently, 
IF was performed to label PLD2 (A) or PLD1 (B) protein with TRITC. Thus, green 
signal represents cells expresing miRNA plasmid and red signal represents PLD protein. 
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Nuclei were stained with DAPI. In green-labeled cells, there was a decrease in PLD (red) 
signal when compared to empty vector and mock conditions. Empty Vector was used as a 
negative control and contains the same plasmid backbone with only the GFP gene. 
Images were taken at 100X magnification on a Nikon 50 Eclipse epifluorescence 
microscope under the same photomicrographic conditions. Images were then overlayed 
using Adobe Photoshop software.  
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Figure 15. Exogenous miRNA decreased PLD lipase activity. (A) PLD lipase activity 
was measured in the presence of individual exogenous miRNA in several cell lines. 
HMEC is a non-cancerous human breast cell line and MCF-7 and MDA-MB-231 cells 
are low and highly aggressive human breast cancer cell lines, respectively. Furthermore, 
MDA-MB-231 cells express the lowest endogenous amount of these miRNA (Figure 12) 
and all of the miRNA tested reduce PLD lipase activity. However, the miRNA have less 
effect in HMEC and MCF-7 cells. It should be noted these two cell lines also express less 
PLD protein. (B) PLD lipase activity was measured in the presence of combinations of 
miRNA in MCF-7 cells. Combinations of miRNA show a greater reduction in PLD lipase 
activity than individual miRNA. A probability (P) of <0.05 indicates significance by the 
student t-test and a significant decrease relative to Control is denoted by (#). In panel A, 
the Control for each cell line was used to compare experimental goups within that cell 
line.  
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Figure 16. Successful transfection of miRNA in human breast cancer cells. MicroRNA-
encoding plasmids were transfected into MCF-7 and MDA-MB-231 cells. MicroRNA 
expression levels were measured by qRT-PCR and expressed relative to U6 as a 
housekeeping gene. Experiments in Figure 13-15 depend on successful transfection of 
miRNA and this figure demonstrates a significant increase in miRNA expression when 
transiently transfected in both cell lines.  
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Figure 17. Luciferase reporter assay supports miRNA binding to PLD mRNA. MDA-
MB-231 cells were co-transfected with miRNA mimics and a luciferase reporter plasmid 
containing the luciferase gene and the PLD2 3’UTR sequence. (A) This reporter plasmid 
is transcribed into a fusion mRNA. If the miRNA mimic binds to the PLD2 3’UTR, it 
will suppress translation of the fusion mRNA and less luciferase will be measured by 
spectrometry. (B) Luciferase signal was decreased in the presence of PLD2-targeting 
miRNA when compared to the control (scramble) mimic and mock conditions. This 
suggests the miRNA can inhibit translation of PLD2 via binding to the 3’UTR. Statistical 
analysis by the student t-test was used with a probability (P) of <0.05 indicating 
significance and a significant decrease relative to Mimic Control is denoted by (#).  
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Subaim 1C: To assess the effect of microRNA regulation of PLD on breast cancer 
cell invasion.  
 
Results 
The overall objective of this study was to investigate the role of miRNAs as 
putative factors responsible for down-regulating PLD in healthy breast cells, and the lack 
thereof resulting in elevated PLD in highly aggressive cancer cells. Selective 
manipulation of gene expression of these miRNAs could be used to alter/control the 
severity of the invasive phenotype of these two human breast cancer cell lines. 
Overexpression of the miRNAs in both the highly aggressive MDA-MB-231 cells and the 
less aggressive MCF-7 cells and subsequent measurement of cell invasion was performed 
(Figure 18). Both the miRNA plasmids and the miRNA mimics were used in both cell 
lines and similar results were observed with both. In MDA-MB-231 cells, cell invasion 
was decreased in the presence of each miRNA individually. However, only miR-203 and 
miR-182 significantly decreased the cell invasion of MCF-7 cells. MCF-7 cells are much 
less invasive to begin with and further, this is consistent with data observed in Subaim 
1B. MicroRNA had less effect on PLD expression and activity in MCF-7 cells compared 
to MDA-MB-231 cells.  
Next, further investigation of miRNA-PLD regulation in invasion was pursued. 
Invasive properties of highly aggressive MDA-MB-231 cells were further increased by 
the overexpression of PLD1 and PLD2, which was then negated by overexpression of 
miRNA targeting each isoform (Figure 19A). MicroRNA-203 was chosen to represent 
PLD2 mRNA-targeting miRNAs due to its consistent inhibition of cell invasion shown in 
Figure 18. 
As a companion experiment, specific siRNAs targeting miR-203 or miR-182 were 
transfected in MDA-MB-231 cells, and cell invasion was evaluated (Figure 19B). Next, 
the appropriate miRNA was co-transfected with the siRNA as a “rescue” experiment. 
Silencing miRNA was predicted to increase cell invasion while co-transfecting miRNA 
with siRNA was predicted to negate the effect of the siRNA. As shown in Figure 19B, 
MDA-MB-231 cells with silenced miR-203 or -182 showed increased invasion compared 
to cells co-transfected with siRNA against miRNA and miRNA mimics.  
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PLD-targeting miRNA expression was decreased in more metastatically invasive 
breast cancer cells (Figure 12), and further experiments were needed to demonstrate the 
molecular mechanism on how this is accomplished. Given that our laboratory has 
reported a role for PLD in metastasis (28), and that exogenous miRNA resulted in larger 
effects in MDA-MB-231 cells than MCF-7 cells, I hypothesized that this negative change 
in miRNA gene expression in highly invasive breast cancer cells was a function of the 
epithelial-mesenchymal transition. Cancer cells that have undergone EMT exhibit a more 
invasive, less differentiated phenotype. MDA-MB-231 cells have a spindle-like 
morphology, increased invasion capability, and limited cell-cell adhesions, whereas 
MCF-7 cells have rounder morphology, are less invasive, and grow in clusters. Thus, 
MDA-MB-231 cells are more representative of post-EMT cells and MCF-7 cells being 
more pre-EMT. Cells can be induced to undergo EMT or the reverse process MET. I used 
E-cadherin as a pre-EMT effector and vimentin as a post-EMT marker to investigate 
miRNA expression in response to EMT changes. Decreasing E-cadherin levels has been 
shown to induce EMT by activating several EMT transcription factors including Snail 
(127,128). 
The relative levels of EMT marker expression in MCF-7 and MDA-MB-231 were 
listed in Figure 20A, supporting their use as pre- and post-EMT cells, respectively. 
Confirmaation of the protein expression of E-cadherin (pre-EMT) and vimentin (post-
EMT) in MCF-7 and MDA-MB-231 cells respectively is shown in Figure 20B. 
MicroRNA expression levels were evaluated when overexpressing EMT markers in 
MDA-MB-231 cells (Figure 21). Two pre-EMT markers (E-cadherin and β-catenin) and 
two post-EMT markers (vimentin and EGFR) were used. The most significant changes 
were detected with miR-3619 expression levels in the presence of E-cadherin and 
vimentin. MicroRNA expression increased in the presence of the pre-EMT marker, E-
cadherin, but was decreased when overexpressing the post-EMT marker vimentin. This is 
consistent with the findings of decreased miRNA expression in highly invasive breast 
cancer cells. Furthermore, by silencing E-cadherin in MCF-7 cells, the decreased miR-
3619 expression is more characteristic of MDA-MB-231 cells (Figure 22A). Conversely, 
by silencing vimentin in MDA-MB-231 cells, an increase miR-182 expression was 
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observed (Figure 22B). These data indicate PLD mRNA-targeting miRNA expression is 
influenced by EMT processes.  
Finally, I am proposing a model (Figure 23) where PLD protein expression is 
down-regulated by a repertoire of microRNAs in healthy breast cells. In cancerous breast 
cells, expression of these miRNAs was suppressed as EMT progressed (particularly with 
the decrease of E-cadherin and appearance of vimentin), leading to increased PLD 
protein production. Furthermore, this surplus of PLD protein subsequently facilitated cell 
invasion, and thereby metastasis. 
 
Aim 1 Conclusions: PLD1 and PLD2 are upregulted in invasive breast cancer cells 
compared to non-cancerous breast cells. Further, a set of miRNA were identified that 
were predicted to bind to PLD1 or PLD2 mRNA 3’UTR and the expression levels of 
these miRNA were inversely related to the protein expression of PLD1 or PLD2 in 
human breast cell lines. Exogenous addition of these miRNA reduced PLD1 and PLD2 
protein expression and enzymatic activity and were able to decrease expression of a 
luciferase reporter plasmid. Physiologically, breast cancer cell invasion was reduced in 
the presence of these miRNA. Finally, the expression of these miRNA responds to EMT 
effectors. I propose that this repertoire of miRNA functions in healthy breast epithelial 
cells to maintain PLD protein at a normal expression level but upon EMT, these miRNA 
are downregulated allowing for an increase in PLD protein and thereby cell invasion.  
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Figure 18. Exogenous miRNA decrease breast cancer cell invasion. MCF-7 or MDA-
MB-231 cells were transfected with miRNA-encoding plasmids (A) or miRNA mimics 
(B) and subjected to Matrigel cell invasion. Number of cells invading decreased in the 
presence of either miRNA plasmids or miRNA mimics, particlulary in the more 
aggressive MDA-MB-231 cells. (C) Representative images of Matrigel inserts of MDA-
MB-231 cell invasion with and without exogenous miRNA. A probability (P) of <0.05 
via the student t-test indicates significance and a significant decrease relative to Mock + 
EGF is denoted by (#).  
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Figure 19. miRNA “rescue” cell invasive phenotype after PLD overexpression. (A) 
MDA-MB-231 cells were transfected with PLD1 (blue) or PLD2 (gray) plasmids and 
subjected to Matrigel cell invasion assay. A greater number of invaded cells were 
observed in PLD overexpressed cells compared to mock treated cells. Subsequently, 
MDA-MB-231 cells were co-overexpressed with either PLD1 or PLD2 and a respective 
miRNA (miR-182 for PLD1 and miR-203 for PLD2). The addition of the miRNA 
reduced the number of cells invading from PLD-overexpressing levels to approximately 
mock levels. (B) MDA-MB-231 cells with silenced miR-203 or -182 showed increased 
invasion compared to cells co-transfected with siRNA against miRNA and miRNA 
mimics. A probability (P) of <0.05 using the student t-test indicates significance and a 
significant increase is denoted by (*) while a significant decrease is denoted by (#).  
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Figure 20. Pre- and post-EMT markers in human breast cancer cell lines. (A) Commonly 
used markers for pre- and post-EMT and their relative expression in a low invasive breast 
cancer cell line (MCF-7) and highly invasive breast cancer cell line (MDA-MB-231). (B) 
Western blot showing protein expression in the cell lines of interest of a pre-EMT marker 
(E-Cadherin) and a post-EMT marker (Vimentin). These data suggest MCF-7 cells are 
representative of pre-EMT cells and MDA-MB-231 cells are representative of post-EMT 
cells.  
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Figure 21. miR-3619 expression in the presence of pre- and post-EMT markers. MDA-
MB-231 cells were transfected with pre-EMT markers E-cadherin and β-catenin (green 
bars) or post-EMT markers vimentin and EGFR (red bars). In the presence of E-cadherin, 
miR-3629 levels increased. However, in the presence of vimentin, miR-3619 levels 
decreased. This expression profile of miR-3619 is consistent with levels in pre- and post-
EMT cells.  
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Figure 22. miRNA expression after silencing EMT markers in human breast cancer cells. 
(A) Pre-EMT MCF-7 cells were silenced for E-cadherin and miR-3619 (PLD2) and 
miR182 (PLD1) expression levels were measured by qRT-PCR. (B) Post-EMT MDA-
MB-231 cells were silenced for vimentin and expression levels of miR-3619 (PLD2) and 
miR-182 (PLD1) were measured by qRT-PCR. (C-D) Western blot analysis shows 
silencing of intended protein, E-cadherin (C) and vimentin (D). Using the student t-test, a 
probability (P) of <0.05 indicates significance and a significant increase is denoted by (*) 
while a significant decrease is denoted by (#).  
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Figure 23. Proposed model of microRNA activity on PLD 3’UTR inhibiting cell 
invasion. In Pre-EMT cells, PLD-targeting miRNA are upregulated, thereby reducing 
PLD protein levels and reducing cell invasion. These miRNA are downregulated in 
response to EMT, allowing elevated protein expression of PLD leading to increased cell 
invasion. Exogenous miRNA, when added to MDA-MB-231 cells, can reduce the cell 
invasion capability via reduction of PLD protein expression and activity.  
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CHAPTER 4. AIM 2. 
 
Specific Aim 2: To study the molecular regulation of classical PLD isoforms in 
breast cancer cells subjected to nutrient starvation.  
 
Rationale 
Phospholipase D (PLD) is a vital enzyme in many tissue types, including healthy 
breast tissue, and its enzymatic products exert influence over an abundance of cellular 
processes, including cytoskeletal rearrangement, membrane trafficking, and cell 
migration (26). Aim 1 demonstrated that PLD1 and PLD2 were upregulated in highly 
invasive breast cancer cells compared to low invasive and non-cancerous cells and the 
process of EMT allows cells to adopt a more invasive phenotype. Furthermore, 
expression of PLD-regulating miRNA responded to EMT effectors. Rapidly proliferating 
tumor cells are often subjected to stressors such as nutrient starvation, hypoxia, and 
overcrowding. Such stressors can promote EMT in tumor cells and promote invasion and 
metastasis. Thus, the miRNA regulation of PLD1 and PLD2 in breast cancer cells under 
stress is of interest to investigate.  
 
Experimental Design 
 The goals of this aim were accomplished with two subaims. First, classical PLD 
protein and gene expression and enzymatic activity were measured under nutrient 
starvation. Nutrient starvation was the chosen stressor due to PLD’s known activation of 
mTOR in cell growth and proliferation. Second, miRNA expression under nutrient 
starvation and any cross-talk between PLD and miRNA expression were investigated.  
In subaim 2A, PLD expression was evaluated by Western blot and qRT-PCR, as 
well as PLD enzymatic activity all under nutrient starvation. Culturing cells with serum-
free media induced nutrient starvation. Three additional cell lines were included, an 
additional highly invasive breast cancer (BT-549), low invasive breast cancer (BT-474), 
and non-cancerous breast cell line (MCF-10A).  
Then, in the second subaim, expression of the miRNA identified in Aim 1 was 
measured by qRT-PCR under conditions of increasing duration of nutrient starvation. 
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Next, the ability of miRNA to regulate PLD expression under nutrient starvation was 
evaluated via the luciferase reporter assay used in Aim 1. PLD expression was correlated 
with cell invasion ability under starvation conditions. Finally, it was investigated whether 
PLD, or its enzymatic product PA, can influence miRNA expression. 
 
Subaim 2A: To evaluate PLD1 and PLD2 expression in breast cancer cells subjected 
to stress. 
 
Results 
To understand the reason for the high level of PLD observed in highly invasive 
cells, I hypothesized that cells in the rapidly growing tumor do not have full access to 
nutrients and begin to migrate out. PLD acts as a “stress-response signal” and its 
expression and activity change during stress conditions encountered in a nutrient 
deprived tumor. Dividing cells and cancer cells have highly anabolic metabolisms in 
order to generate the molecules needed to increase cell mass and successfully divide. It 
has been proposed that phosphatidic acid is an indicator of nutrient sufficiency due to its 
role in activating mTOR and the role of PLD as a stress response protein and further that 
cancer cell proliferation is PLD dependent (129,130).  
Knowing that nutrient starvation of cancer cells is important to the expression of 
certain transcription factors and key signaling proteins that ultimately contribute to 
cancer cell survival, proliferation, and migration (40,41), PLD expression and enzymatic 
activity was tested in several human breast cancer cell lines and normal cells following 
serum starvation as a function of time. An increase in relative pld1 and pld2 gene 
expression was observed (Figure 24) that after approximately 6 hours remained relatively 
constant in most cell lines. This increase was most pronounced in the breast cancer cell 
lines, especially the highly aggressive MDA-MB-231 and BT-549 cells. A less robust yet 
still significant increase was observed in the less aggressive breast cancer cell lines, 
MCF-7 and BT-474.  
Interestingly, PLD protein expression followed a different pattern in response to 
serum starvation. Starvation resulted in an initial steady increase in protein expression 
(Figure 25A-B) that peaked between 6 and 12 hours of starvation. After this point, PLD 
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protein levels returned to basal levels (or below) after prolonged (24 hour) starvation. 
This biphasic trend of PLD protein expression in response to starvation was observed in 
both MCF-7 and MDA-MB-231 cells. PLD lipase activity was also measured after 
increasing duration of starvation (Figure 25C), and the activity followed a similar 
biphasic pattern as protein expression. Furthermore, evaluation of MDA-MB-231 cell 
invasion after starvation correlated with PLD protein expression and lipase activity 
(Figure 26). Cell invasion increased initially with cell starvation but had returned to basal 
levels by 24 hours of starvation.   
MicroRNA inhibit protein translation without necessarily reducing mRNA levels. 
Thus, I hypothesized that the molecular mechansim behind the biphasic PLD protein 
expression despite the steady increase in pld gene expression could be due to miRNA 
regulation. Therefore, evaluation of miRNA regulation of PLD during starvation was the 
focus of Subaim 2B.  
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Figure 24. pld1 and pld2 mRNA levels after starvation in multiple human breast cell 
lines, cancerous and non-cancerous. Cells were subjected to nutrient starvation for up to 
24 hours, were collected at 0, 6, 18, and 24 hours post-starvation. pld1 (A) and pld2 (B) 
mRNA abundance were then measured by qRT-PCR. Both pld1 and pld2 gene 
expression increased with increasing duration of starvation, especially in the breast 
cancer cell lines (MDA-MB-231, BT-549, MCF-7, and BT-474). A probability (P) of 
<0.05 by student t-test indicates significance and a significant increase is denoted by (*). 
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Figure 25. PLD protein expression and lipase activity after starvation. (A-B) MCF-7 and 
MDA-MB-231 cells were subjected to nutrient starvation for 24 hours. Cells were 
collected at 0, 3, 6, 12, and 24 hours post starvation. Western blot analysis shows PLD1 
(A) and PLD2 (B) protein expression in response to starvation. Both isoforms in both cell 
lines show a peak protein expression between 6-12 hours of starvation that subsequently 
returns to near basal levels by 24 hours of starvation. This is in contrast to the gene 
expression data shown in Figure 24. (C) PLD lipase activity shows a similar trend, 
peaking between 6 to 12 hours of starvation and returning to basal activity by 24 hours of 
starvation. A probability (P) of <0.05 by student t-test indicates significance and a 
significant increase is denoted by (*). 
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Figure 26. Cell invasion of MDA-MB-231 cells after increasing starvation. MDA-MB-
231 cells were subjected to nutrient starvation for 24 hours. Cells were collected after 0, 
3, 6, 12, and 24 hours of starvation and subsequently used in a Matrigel invasion assay. 
Cell invasion increases initially and peaks at 6 hours of starvation, returning to basal 
levels by 24 hours of starvation. These data correlate with PLD protein and lipase activity 
in response to starvation (Figure 25). A probability (P) of <0.05 by student t-test indicates 
significance and a significant increase is denoted by (*). 
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Subaim 2B: To study microRNA regulation of PLD1 and PLD2 in breast cancer 
cells under nutrient starvation.  
 
Results 
First, the expression levels of the miRNA in breast cancer cells as a function of 
increasing starvation duration was evaluated. As shown in Figure 27, the expression of all 
of the PLD mRNA-targeting miRNAs tested here varied upon starvation. Interestinly, 
initially (up to 6 hours) several miRNAs were baseline, whereas beginning at 
approximately 6 hours miRNA expression increased up to 24 hours of starvation. The 
time of the miRNA increase (6-12 hours) corresponds to the peak of PLD protein 
expression. Thus, during the time points when miRNA levels were highest, PLD protein 
was lowest, suggesting the increase in miRNA could be responsible for the observed 
decrease in PLD protein. MicroRNA expression was measured in both MCF-7 (gray 
graphs) and MDA-MB-231 cells (blue graphs). The largest increases in miRNA 
expression for the MDA-MB-231 cells were the PLD2 mRNA-targeting miR-887 and the 
PLD1 mRNA-targeting miR-182. However, the changes for each individual miRNA were 
typically larger fold increases in MCF-7 cells than MDA-MB-231 cells. Further, miRNA 
levels in non-cancerous MCF-10A cells were measured using the same time points 
measured for MCF-7 and MDA-MB-231 cells (Figure 28). Only minor changes in 
miRNA expression were observed in MCF-10A cells suggesting this process is specific 
to the cancer cell lines. The data indicate that one of the fundamental and significant 
differences between cancer and non-cancer cells is that the former are able to modulate 
their response to environmental cues (in this case starvation) by increasing or decreasing 
microRNAs. 
To gain more direct evidence that miRNA regulate PLD protein translation during 
prolonged starvation, a luciferase reporter assay was used to study PLD2 translation in 
the presence of miRNA and under starvation conditions. In cells containing only the 
PLD2 reporter plasmid, an initial increase in luciferase signal was observed, followed by 
a decreased signal with prolonged nutrient starvation (Figure 29B). Further, when 
miRNA mimics were added prior to beginning starvation, the initial spike in luciferase 
signal was diminished and there was an even greater decrease in luciferase signal by 24 
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hours of starvation. This suggests that the presence of miRNA can inhibit the increase of 
PLD protein production in reponse to starvation and further that miRNA could be 
eliciting the downregulation of PLD protein observed with prolonged starvation.  
This initial increase in PLD activity caught my attention, which I hypothesized 
could be related to other well-known biological phenomena in which PLD is implicated, 
namely, regulation of mTOR, as it is linked to nutrient response. An activated mTOR 
pathway (including ribosomal S6K) results in increased cell growth and proliferation. I 
predict that as a highly sensitive stress response protein, PLD protein levels initially 
increases during nutrient starvation, facilitating cell migration. One could reason at this 
point that the initial increase in PLD serves as a stress response in the cell that allows 
functions other than nutrient-related to occur, such as cell migration that could be 
encountered initially in tumor cells lacking nutrients. I also hypothesize a second phase 
exists in the starved cell when mTOR and S6K were no longer activated by PA (as PLD 
is low). Under these conditions, cell migration ceases, at which point nutrient 
conservation and autophagy begin. 
Aim 1 showed that miRNA reduced PLD protein expression and based on the 
results of this study so far and the biphasic nature of PLD protein expression during 
starvation, I hypothesized that a mechanism of negative feedback exists in which the 
enzymatic product of PLD, PA, increases expression of miRNA with subsequent post-
translational regulation of PLD. To reproduce the effects of prolonged nutrient starvation 
on miRNA, cancer cells were incubated with DOPA (1,2-dioleoyl-sn-glycero-3-
phosphate), the commericially available PA most similar to the PA produced by PLD. 
Prolonged incubation (4 hour) resulted in an increase in miRNA gene expression (Figure 
30B and D) compared to a slight decrease in gene expression after only 20 min of 
incubation (Figure 30A and C). 
In rapidly growing tumors, cells often lack full access to nutrients. Starvation 
induces a stress response in these cells, leading to many cellular changes, including 
elevated protein expression of PLD. For its established roles in signaling pathways and 
cell migration, the observed increase in PLD protein aids cell invasion. With prolonged 
starvation (24 hours), PLD protein levels decreased to below basal level. Additionally, an 
increase in gene expression of the miRNAs targeting PLD was found. The increase in 
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miRNA gene expression correlated with decreased PLD protein expression. Therefore, I 
propose a model in which the enzymatic product of PLD, PA, mediates an increase in 
miRNA gene expression (Figure 31). 
 
Aim 2 Conclusions:  
In response to nutrient stavation, PLD protein exhibited biphasic expression. This 
may be explained by the induction of PLD-regulatory miRNA gene expression with 
prolonged starvation. I propose a model whereby the PLD enzymatic product 
phosphatidic acid (PA) induced a miRNA-mediated negative feedback on PLD protein 
expression in prolonged nutrient starvation of breast cancer cells.  
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Figure 27. miRNA expression after starvation in breast cancer cells. PLD-targeting 
microRNA expression is increased in breast cancer cells in response to long-term 
starvation. (A-H) Cells were deprived of serum for the indicated lengths of time. qRT-
PCR was performed to measure endogenous levels of miRNAs, i.e., miR-182 (A, B), 
miR-203 (C, D), miR-887 (E, F), and miR-3619-5p (G, H) in MCF-7 cells and MDA-
MB-231 cells, respectively. A probability (P) of <0.05 by the student t-test, indicates 
significance and a significant increase is denoted by (*) while a significant decrease is 
denoted by (#).  
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Figure 28. miRNA expression after starvation in non-cancerous breast cells. Endogenous 
gene expression of PLD-targeting miRNAs under nonstarved and starved (24 h) 
conditions was measured by qRT-PCR in noncancerous human breast cells, MCF-10A. A 
probability (P) of <0.05 by the student t-test, indicates significance and a significant 
increase is denoted by (*) while a significant decrease is denoted by (#).  
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Figure 29. Luciferase assay shows miRNA inhibit increase in protein after starvation. 
(A) Luciferase reporter and scheme of cotransfections with miRNAs. (B) Luciferase 
reporter assay shows decreased PLD2 protein production in the presence of miRNA with 
increasing duration of starvation in MCF-7 cells. A probability (P) of <0.05 indicates 
significance, by the student t-test, and a significant increase is denoted by (*) while a 
significant decrease is denoted by (#).  
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Figure 30. miRNA expression in breast cancer cells after stimulation with PA. Gene 
expression of miR-203, miR-887, miR-3619-5p, and miR-182 after incubation with 
increasing amounts of DOPA (1,2-dioleoyl-sn-glycero-3-phosphate) for 20 min or 4 h in 
MCF-7 or MDA-MB-231 cells. Note that the y-axis scales are different in panels B and D 
since miRNA expression varies in cell line and with time stimulated with PA.  
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Figure 31. Model depicting the proposed effect of starvation on microRNA in cancer 
cells. Initially, when placed under starvation conditions, cancer cells increase protein 
expression of the stress response protein PLD. The enzymatic product of PLD, PA, 
subsequently serves to signal miRNA gene expression, thereby regulating PLD protein 
translation in a negative-feedback pathway. The model compiles the repertoire of 
miRNAs that suppress PLD translation in response to an elevated PA level. The elevated 
PLD level results in a rise of the cellular PA level, therefore inducing expression of 
miRNAs that suppress PLD translation. PLD gene, protein, and activity are enhanced 
specifically in cancer cells under conditions of cellular stress frequently occurring at the 
tumor core, such as hypoxia, starvation, or overconfluence. This elevation of PLD 
activity results in an increased expression of multiple miRNAs in low-invasive tumor 
cells leading to feedback inhibition of PLD expression. However, high-invasive tumor 
cells lose the ability to induce these miRNAs, resulting in an uncontrolled PA level and 
the subsequent inhibition of apoptosis through the mTOR pathway. 
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CHAPTER 5. AIM 3. 
Specific Aim 3: To determine the effect of upregulated PLD6 on breast cancer cell 
invasion.  
 
Rationale 
PLD6, a “non-classical” PLD isoform that is localized in the outer mitochondrial 
membrane, has been found to be upregulated in mammary tumors by von Eyss et al 
(131). Von Eyss et al. demonstrated that the oncogenic transcription factor c-myc directly 
binds the PLD6 promoter inducing transcription (131). Myc expression is often 
dysregulated in triple negative breast cancer, which is the subtype MDA-MB-231 cells 
represent (131). Myc promotes cell growth and proliferation, contributing to the 
aggressive nature of triple negative breast cancer cells (131). As a downstream effector of 
myc, PLD6 was investigated in the context of breast cancer cell invasion.  
While still understudied, it is known that PLD6 hydrolyzes cardiolipin to generate 
PA and thereby promote mitochondrial fusion (132). In turn, mitochondrial fusion 
inhibits apoptosis and enables the cell to cope with stress and perform more oxidative 
phosphorylation. In tumor cells that are rapidly proliferating, increased mitochondrial 
fusion and ATP generation as well as decreased apoptosis would be highly beneficial. 
Thus, it would seem logical to assume that overexpression of PLD6 would promote cell 
growth and energy production necessary for tumor cells. Preliminary results indicated the 
localization of PLD6 in the leading edge, lamellipodia, of breast cancer cells, suggesting 
PLD6 has a role in breast cancer cell invasion. Herein, the hypothesis that upregulation of 
PLD6 in breast cancer cells promotes cell invasion was investigated.  
 
Experimental Design 
 In the first subaim, the expression PLD6 in three breast cancer cell lines was 
determined via Western blot and qRT-PCR under basal condition. As additional evidence 
of PLD6 expression in breast cancer patient tumors, data mined from the oncomine 
database was presented. Immunofluorescence microscopy was used to determine the 
subcellular localization of PLD6 in breast cancer cells compared to non-cancerous breast 
cells. Finally, to investigate PLD6 in a tumor environment, immunohistochemistry to 
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detect PLD6 protein was performed in ex vivo tumors of xenotransplanted MDA-MB-231 
cells into mice.  
In the second subaim, the effect of starvation and EGF stimulation on PLD6 
expression and subcellular localization was evaluated by Western blot and IF 
microscopy. Nuclear fractionation coupled with Western blot analysis as well as confocal 
microscopy was used to study possible nuclear localization of PLD6. In parallel, PLD6 
protein at the membrane ruffling of lamellipodia was oberseved using 
immunofluorescence microscopy. Finally, cell invasion was evaluated with the 
overexpression or silencing of PLD6.   
 
Subaim 3A: To establish the expression of PLD6 in breast cancer cells.  
 
Results 
As shown in Figure 32A, data mined from the Oncomine database (oncomine.org) 
supports an increase in PLD6 in human invasive breast cancer tumors when compared to 
adjacent normal tissue. The Finak breast study (133) performed microarray ananlysis on 
53 human tumor samples and adjacent normal tissue. However, the study included 
several subtypes of invasive breast cancer, (mined by Karen Henkels). The microarray 
analyses show an increase in PLD mRNA in invasive breast tumors with a p value of 
0.0273, however, a much smaller p value is expected to support significance in studies of 
this kind. Therefore, this data is presented as further supporting the notion that PLD6 may 
be elevated in certain types of invasive breast tumors.   
Pld6 mRNA (Figure 32B) and protein (Figure 32C) levels were evaluated in 
HMEC cells (non-cancerous breast cells), MCF-7 cells (low aggressive breast cancer), 
and MDA-MB-231 cells (highly aggressive breast cells). Protein and mRNA levels were 
measured by Western blot and qRT-PCR respectively from untreated whole cell lysates. 
Both PLD6 protein and mRNA were elevated in MDA-MB-231 cells when compared to 
HMEC and MCF-7 cells, indicating that PLD6 may be important in invasive breast 
cancer cells.  
Previous research in the field has shown that PLD6 protein localizes to the outer 
mitochondrial membrane in normal cells, however it is unknown if a similar localization 
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pattern exists in breast cancer cells. Therefore, immunofluorescence microscopy of 
HMEC and MDA-MB-231 cells was completed using antibody specific for PLD6 protein 
in combination with a mitochondrial marker, called MitoTracker Red Fluorescent Protein 
(RFP) (Figure 33). PLD6 protein was not detectable in IF images of MCF-7 cells. 
However, PLD6 protein co-localized with mitochondria in both HMEC and MDA-MB-
231 cells (Figure 33). Further, there was more PLD6 staining in MDA-MB-231 cells than 
HMEC cells, which is consistent with PLD6 levels from the Western blot and qRT-PCR 
data.  
Our lab recently xenotransplanted MDA-MB-231 cells into immunocompromised 
mice and investigated the role of PLD1 and PLD2 in tumorigenesis (28). Here, 
immunohistochemistry was performed on mouse mammary tumor sections from a similar 
study to evaluate PLD6 protein expression in these tumors. IF microscopy revealed 
positive PLD6 staining at the periphery of the wild type MDA-MB-231 primary 
mammary tumor (Figure 34). In mice that were xenotransplanted with MDA-MB-231 
cells stably transfected with shPLD2, diminished PLD6 staining was observed in the 
mammary tumors. The authors of a previous study (28) demonstrated that the shPLD2 
MDA-MB-231 tumors were less aggressive, producing smaller primary tumors and less 
distant metastases. Additionally, Henkels et al. (28) found that inhibiting PLD2 resulted 
in a better outcome than inhibiting PLD1, meaning smaller primary tumors and less lung 
metastases.  Furthermore, the shPLD2 was MISSION shRNA from Sigma-Aldrich (cat 
no. NM_002663) and no corresponding sequence was found in the 3’UTR of PLD6, 
suggesting there is no off-target effect of the shPLD2 on PLD6 mRNA. This lends further 
support for PLD6 having a role in breast cancer cell invasion.  
Having identified PLD6 in xenotransplanted mammary tumors, further 
investigation into the localization of PLD6 within these tumor was conducted.  Serial 
sections of the same tumors were stained with hematoxylin and eosin (Figure 35). 
Skeletal muscle and adipose cells are easily identifiable by their unique appearance and 
are denoted in the figure. The tumor peripheries show stronger purple hematoxylin 
staining of nuclei indicating higher levels of living cells. In contrast, areas of 
predominately pink eosin staining show a decrease in nuclei and represent regions where 
cell death has occurred. This is consistent with necrosis of a hypoxic and starved core of 
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a rapidly proliferating tumor. Comparing the H&E slides with the IF slides, PLD6 
staining appears to co-localize with regions of strong hematoxylin staining. This 
represents the highest density of living cells that are most likely to invade. In the shPLD2 
tumor, there was a larger region of strong hematoxylin staining and less cell death 
observered. This observation suggests a tumor where growth rate does not exceed the 
available nutrients and oxygen, thereby reducing cell death. In the original mouse study, 
the authors found the shPLD2 cells generated a less aggressive tumor resulting in a 
smaller primary tumor with less distant metastases formed, and as such, their need for 
elevated PLD6 activity is be diminished.   
Tumors are a heterogenous collection of cells including cancerous cells as well as 
other resident stromal cells such as fibroblasts, immune cells, adipose cells, and epithelial 
cells (134). In the xenotransplanted tumor model, human MDA-MB-231 cells were 
injected into SCID mice, meaning in the tumors were comprised of human cancer cells 
and mouse stromal cells. Because the PLD6 antibody used detects both human and mouse 
PLD6, the cells showing positive PLD6 staining could not be definitively identified as 
either human or mouse. Therefore, PLD6 protein levels were evaluated in the MDA-MB-
231 cell lines that had been stably silenced with shRNA, either shControl or shPLD2. A 
decrease in PLD6 protein was observed in shPLD2 cells when compared to shControl 
(Figure 36). Thus, I propose that the shPLD2 cells in the tumor contain less PLD6 than 
their shControl or wild type counterparts. Further, it is well known that cancer cells 
communicate with cells in the tumor microenvironment, (134), therefore posing an 
intriguing question of whether PLD6 levels in cancer cells affects PLD6 levels in tumor 
stromal cells. However, PLD6 levels in mouse tumor-associated cells was not evaluated 
at this time. A more definitive answer could be achieved using microdissection to isolate 
the stromal cells from the tumor and analyzing PLD6 protein or gene levels and 
compared to adjacent normal tissue.  
In this subaim, elevated transcript and protein expression of PLD6 was shown in 
triple negative, invasive MDA-MB-231 cells when compared to non-cancerous cells. 
Further, PLD6 localized to the mitochondria under basal conditions in HMEC and MDA-
MB-231 cells. Finally, PLD6 protein was detected in breast cancer tumors from 
xenotransplanted mice.  
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Figure 32. PLD6 expression in breast cancer cells. (A) Data mined from the Finak Breast 
Study on the Oncomine Database shows an increase in pld6 gene expression in invasive 
breast cancer tissue when compared to adjacent non-cancerous tissue. (B-C) pld6 gene 
(B) and protein (C) expression were measured by qRT-PCR and Western blot 
respectively in a non-cancerous human breast cell line (HMEC), a low aggressive breast 
cancer cell line (MCF-7), and a highly aggressive breast cancer cell line (MDA-MB-231). 
Both PLD6 mRNA and protein are elevated in the highly aggressive MDA-MB-231 cells. 
Error bars represent SEM and a probability (P) of <0.05 indicates significance as 
calculated with the student t-test. A significant increase is denoted by (*) while a 
significant decrease is denoted by (#).  
 
 
A 
74	
 
Figure 33. Flurosence microscopy of PLD6 and MitoTracker in breast cells. Endogenous 
PLD6 localizes to the mitochondria in HMEC and MDA-MB-231 cells. PLD6 protein is 
labeled green with FITC and mitochondria were labeled red with MitroTracker-RFP. 
Images were taken at 100x magnification on a Nikon 50 Eclipse epifluorescence 
microscope and pictures were overlayed using Adobe Photoshop software.  
 
 
 
 
 
 
 
 
 
 
 
 
75	
 
 
Figure 34. PLD6 expression in xenotransplanted mammary tumors. MDA-MB-231 cells 
were xenotransplanted into SCID mice and tumors were allowed to grow (28). Three 
conditions are shown here: Intact MDA-MB-231 cells and MDA-MB-231 cells that have 
been stably transfected with either Control or PLD2 short hairpin (sh) RNA. This study 
demonstrated that shPLD2 MDA-MB-231 cells, but not the shControl cells, formed 
smaller primary tumors and less lung metastases, indicative of a less aggressive cancer. 
Here, the shPLD2 tumors are being used as representative of a less invasive breast cancer 
phenotype. Serial sections of primary tumors were fixed onto microscope slides and 
stained with anti-PLD6-FITC antibody and DAPI stain. IF images were taken at 10X 
magnification and images were overlayed using Adobe Photoshop software. As indicated 
by the white arrows, a band of higher intensity PLD6 staining was observed near the 
tumor periphery. However, this staining is absent in the less aggressive shPLD2 samples.  
 
200 µm 
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Figure 35. H&E staining of xenotransplanted mammary tumors. Hematoxylin and eosin 
staining was performed on serial sections of the same tumors prepared in Figure 34. 
Black arrows point to the tumor periphery where abundant purple hematoxylin staining 
indicates a high cell density of living cells. Areas of pink eosin stainging, denoted by **, 
represent regions of higher cell death more similar to a necrotic tumor core. White 
arrowheads indicate non-stained adipose cells. Skeletal muscle adjacent to the wild type 
tumor is denoted by SM. Larger regions of cell death are observed in the wild type and 
shControl tumors consistent with necrotic cores of rapidly growing tumors. Images were 
taken at 10x magnification.  
 
 
200 µm 
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Figure 36. PLD6 levels in MDA-MB-231 cell lines stably transfected with control and 
PLD2 shRNAs. PLD6 protein level was determined by Western blot in MDA-MB-231 
cells stably transfected with either shControl or shPLD2. GAPDH was used as a loading 
control.  
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Subaim 3B: To determine the effect of starvation and EGF signaling on PLD6 
expression and subcellular localization on breast cancer cell invasion.  
 
Results 
Starvation and EGF signaling promote cell invasion and increase PLD1 and PLD2 
signaling as demonstrated in Aims 1 and 2. However, the effect of starvation and EGF 
signaling on PLD6 remains unknown. PLD1 and PLD2 protein expression change in 
response to starvation (Aim 2), indicating that these PLD isoforms can be considered as 
“stress-response proteins”. Here it was investigated if this phenomenon was applicable to 
the PLD6 isoform, particularly since PLD6 localizes to the mitochnodria and starved 
cells could have functional changes in oxidative metabolism. First, MDA-MB-231 cells 
and MCF-7 cells were serum starved for up to 24 hours, and then, PLD6 protein was 
measured by Western blot and by immunofluorescence microscopy. Using Western blot 
analyses, there was no obvious change in the levels of PLD6 protein expression in MDA-
MB-231 cells as a function of increasing starvation time (Figure 37A). PLD6 protein was 
not detectable in MCF-7 cells at any time pre- or post-starvation (Figure 37). MDA-MB-
231 cells cultured for IF microscopy were starved and treated with EGF for 15 minutes. 
Two methods of EGF treatment were used. One was global application of 10 nM EGF in 
starvation media incubated with cells, denoted global EGF. Alternatively, a concentrated 
amount of EGF was added in one corner of the well, denoted localized EGF. IF staining 
of these cells indicate PLD6 moving away from mitochondria (MitoTracker-RFP) 
towards a more diffuse localization throughout the cytoplasm and also possibly within the 
nucleus (Figure 37B). This would be the first documentation of PLD6 localizing in the 
nucleus, even though PLD6 is not predicted to contain a nuclear localization signal 
(NLS). PLD6 does contain a MLS (132), and there can be overlap between MLS and 
NLS sequences such as an abundance of lysine and arginine residues (135). Figure 38 
shows the amino acid sequence of PLD6 protein, denoting the MLS and potential NLS. 
Amino acid sequences rich in lysines or arginines often comprise an NLS. The MLS of 
PLD6 ends in a string of arginines that could serve as a NLS. Alternatively, PLD6 could 
associate with other proteins and be shuttled into the nucleus.  
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Next, nuclear fractionation was used to investigate the potential nuclear 
localization of PLD6 (Figure 39). MDA-MB-231 cells were starved for up to 24 hours 
and were then collected at 0, 3, 6, 12, and 24 hours after the beginning of starvation. The 
cell pellets were next subjected to nuclear fractionation and PLD6 protein was measured 
by Western blot. GAPDH detection in the cytoplasmic fraction and Histone H3 detection 
in the nuclear fraction suggested successful nuclear fractionation. Using this approach, 
PLD6 was only detected in the cytoplasmic fraction (Figure 39A). Additionally, MDA-
MB-231 cells were starved overnight and subsequently treated with 10 nM EGF for 15 
minutes. These cells were subjected to nuclear fractionation and PLD6 protein analyzed 
by Western blot. Again, PLD6 was only detected in the cytoplasmic fractions (Figure 
39B). Nuclear fraction assays are susceptible to protein leakage from from the nuclear 
fraction and therefore the fractionation Western blot was probed for a soluble nuclear 
protein, p53 transcription factor. p53 protein was detected in both the cytoplasmic and 
nuclear fractions (Figure 39A). While it is expected to detect some p53 in the cytoplasm 
due to protein synthesis and p53 signaling, higher levels should be observed in the 
nuclear fraction since p53 is a transcription factor. This suggests the nuclear fractionation 
experiments may have encountered protein leakage and thus these experiments cannot 
definitively exclude PLD6 from the nucleus.  
To further investigate nuclear localization of PLD6, immunoflourescent confocal 
microscopy of MDA-MB-231 cells was used (Figure 40). MDA-MB-231 cells were 
serum starved overnight and treated with 10 nM EGF for 15 minutes. As shown in Figure 
37B, these treatments produced a population of cells with apparent nuclear PLD6 
staining. EGF-treated MDA-MB-231 cells were stained with FITC-labeled anti-PLD6 
antibody, RFP-MitoTracker, and DAPI. An Olympus FV1000 confocal microscope was 
used to image 0.3 µm slices at 60 x magnification with 1.5 digital zoom. Serial images 
are shown in Figure 40 with the first image being closest to the glass slide and 
progressing upward in the z-axis.  The red MitoTracker stain began perinulcear and 
below the nucleus. Going upward, a nuclear outline was obvious with perinuclear 
MitoTracker staining. However, a degree of green PLD6 staining was observed in the 
nuclear region all slices in some cells. Those cells are denoted with white arrows in 
Figure 40. In other cells, a clearly defined nuclear region devoid of red and green signal 
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was present. This suggests some cells may exhibit nuclear PLD6 localization and further 
quantification is necessary to determine the number of cells with PLD6 nuclear staining 
in each condition. This effect may not directly be due to EGF stimulation as not all cells 
on the same slide or field demonstrate the same nuclear PLD6 staining. Silencing PLD6 
in MDA-MB-231 cells and the subsequent devoid of PLD6 antibody staining in the 
nucleus by confocal microscopy would lend further support to PLD6 nuclear localization. 
Additional controls are needed to further support PLD6 staining within the nucleus. 
These include secondary antibody alone or isotype control to illustrate any non-specific 
binding of secondary antibody. Furthermore, another nuclear stain that does not directly 
target DNA or DNA-associated proteins would  
Next, PLD6 localization to sites of membrane ruffling and cell adhesion prior to 
the formation of lamellipodia in invasive cells was investigated with immunofluorescence 
microscopy. As shown in Figure 37, a more diffuse staining of PLD6 protein was 
observed after starvation and EGF stimulation, including staining at cell margins. MDA-
MB-231 cells were co-transfected with PLD6 and either Cdc42 or PAK1. Cdc42 is a Rho 
family GTPase involved in cytoskeletal rearrangement, cell-to-cell adhesion, and cell 
migration. PAK1 is a serine/threonine kinase and a target for GTP binding proteins 
Ccd42 and Rac. In this manner, both Cdc42 and PAK1 regulate cytoskeletal 
rearrangement necessary for cell motility. These transfection conditions are being used 
here to induce an obvious invasive cell phenotype. Forty-eight hours post transfection 
these cells were stained for IF microscopy to evaluate PLD6 expression in lamellipodia. 
Cells were additionally stained with MitoTracker-RFP or with TRITC-labeled Phalloidin 
stain. As controls, cells that were transfected with PLD6 alone and also PLD6-
overexpressing cells that were additionally treated with 10 nM EGF were included. As 
shown in Figure 41, transfection of PLD6 alone did not show PLD6 protein near the 
plasma membrane of cells. However treatement with EGF produced cells with an 
invasive morphology and PLD6 staining at membrane ruffling. Similar staining was 
observed for PLD6 in cells co-transfected with Cdc42 or PAK1. PLD6 staining was 
interspersed with phalloidin at the membrane ruffling of lamellipodia in these cells.  
Finally, the effect of PLD6 overexpression or silencing on breast cancer cell 
invasion was investigated (Figure 42). PLD6 was overexpressed in MCF-7 cells, as well 
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as MDA-MB-231 cells. Additionally, PLD6 was silenced with siRNA in MDA-MB-231 
cells. Forty-eight hours post-transfection, these cells were collected and were used for 
Matrigel invasion assays. Cells were starved for 2 hours prior to invasion and 10 nM EGF 
was used as a chemoattractant. Silencing and overexpression were confirmed via Western 
blot and qRT-PCR (Figure 43). Overexpressing PLD6 in MDA-MB-231 cells increased 
breast cancer cell invasion and conversely, silencing PLD6 in MDA-MB-231 cells 
significantly reduced in the number of invading cells. However, overexpression of PLD6 
in MCF-7 cells had no significant effect on the number of cells that invaded the Matrigel 
inserts. Successful transfection of PLD6 is shown in Figure 43C with an increase in 
PLD6 protein levels 48 hours after transfection. Data from Aim 1 demonstrated that 
overexpression of PLD1 and PLD2 increased cell invasion of both MCF-7 and MDA-
MB-231 cells. Likewise, silencing PLD1 and PLD2 in MDA-MB-231 cells decreased 
cell invasion. Thus, Western blot analysis was done of the protein levels of PLD1 and 
PLD2 in MDA-MB-231 cells in the presence of 50 nM siPLD6 (Figure 43). Compared to 
the scramble control (siNEG), PLD1 and PLD2 protein levels do not decrease when 
silencing PLD6. This further supports that the cell invasion effect observed by silencing 
PLD6 is in fact from diminished PLD6 levels and not concomitant silencing of PLD1 or 
PLD2. Noteworthy, is the decreased PLD1 and PLD2 protein expression in the siNEG 
compared to the Mock transfection (Figure 43). This suggests an offtarget effect of 
siRNA on PLD1 and PLD2 protein expression. While siPLD6 does not further decrease 
PLD1 and PLD2 protein below siNEG levels, there was an observed decrease below 
Mock transfection conditions. This decrease in PLD1 and PLD2 protein from mock 
levels could impact the cells. Therefore, the decreased PLD1 and PLD2 protein could 
have contributed to the decreased cell invasion observed in MDA-MB-231 cells with 
siRNA against PLD6 (Figure 42C).  
 
Aim 3 Conclusions: 
 PLD6 is upregulated in invasive breast cancer cells and is also found in PLD2-
overexpressing MDA-MB-231 xenotransplanted tumors. Under basal conditions, PLD6 
localizes to the mitochondria but upon starvation or EGF treatment, PLD6 adopts a more 
diffuse localization in the cytoplasm with possible nuclear localization. Total PLD6 
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protein does not change under these conditions but PLD6 is recruited to lamellipodia. 
Finally, the presence of PLD6 promotes breast cancer cell invasion in MDA-MB-231 
cells.  
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Figure 37. Endogenous PLD6 expression and subcellular localization after starvation and 
EGF stimulation. (A) MDA-MB-231 and MCF-7 cells were starved for up to 24 hours 
and collected at the indicated times of starvation duration. Whole cell lysates were used 
for Western blot analysis to detect PLD6 protein levels. Levels of PLD6 protein appear 
unchanged in MDA-MB-231 cells during the starvation time course and further, PLD6 
protein was not detected in MCF-7 cells. (B) MDA-MB-231 cells were treated either with 
starvation overnight, starvation + global (10 nM) EGF for 15 minutes, or starvation + 
localized deposit of EGF, incubated for 15 minutes. Placement of EGF in localized 
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treatment is intidicate by white *. White arrows indicate PLD6 staining near the cell 
periphery. Cells were stained red with MitoTracker-RFP and green with FITC-labeled 
anti-PLD6 antibody. Nuclei are stained blue with DAPI. Images were taken at 100x 
magnification and images were merged using Adobe Photoshop software.  
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Human PLD6: 
 
MGRLSWQVAAAAAVGLALTLEALPWVLRWLRSRRRRPRREAPFFPSQVTCT
EALLRAPGAELAELPEGCPCGLPHGESALSRLLRALLAARASLDLCLFAFSSPQ
LGHAVQLLHQRGVRVRVVTDCDYMALNGSQIGLLRKAGIQVRHDQDPGYMHH
KFAIVDKRVLITGSLNWTTQAIQNNRENVLITEDDEYVRLFLEEFERIWEQFNPT
KYTFFPPKKSHGSCAPPVSRAGGRLLSWHRTCGTSSESQT 
 
Figure 38. Human PLD6 amino acid sequence. The mitochondrial localization signal 
(MLS) as validated by (132) is highlighted in blue and consists of the first 39 amino 
acids. Within the MLS there is a string of arginines (in red), which could potentially 
serve as a nuclear localization signal (NLS). Additionally, the catalytic HKD motif is 
highlighted in green.  
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Figure 39. Nuclear fractionation and measurement of PLD6 protein expression. (A) 
MDA-MB-231 cells were subjected to a starvation time course, collected, and subcellular 
fractionation was performed. (B) Alternatively, MDA-MB-231 cells were either starved 
overnight alone or starved and subsequently treated with 30 nM EGF for 15 minutes. 
Cells were collected and subcellular fractionation was performed. PLD6 protein was only 
detected in the cytoplasmic fractions. In both experiments, GAPDH was used as a 
cytosolic marker while Histone H3 was used as a nuclear marker. p53 protein was used as 
a soluble nuclear protein and the level of p53 in the cytoplasmic fraction may indicate a 
degree of leakage from the nuclear fractions.  
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Figure 40. Confocal microscopy images of endogenous PLD6 in EGF-treated MDA-
MB-231 cells. MDA-MB-231 cells were serum starved overnight and subsequently 
treated with 10 nM EGF for 15 minutes. Endogenous PLD6 protein was stained with 
FITC-labeled anti-PLD6 antibody. MitoTracker-RFP stained mitochondria red. DAPI-
stained nuclei appear blue. Images were captured at 60x magnification with 1.5 Digital 
Zoom on an Olympus FV1000 confocal microscope. Serial images were taken at 0.3 µm 
apart on the z-axis. Image 1 in the upper left corner is the section closest to the glass 
cover slip and subsequent images progress upward to the top of the cell in the z-axis. 
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Only the final image contains all three filters. DAPI was removed from the other images 
to illustrate FITC staining in the nuclear region. White arrows indicate cells with nuclear 
PLD6 staining.  
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Figure 41. PLD6 expression in MDA-MB-231. MDA-MB-231 cells were transfected 
with PLD6 alone or co-transfected with PLD6 and Cdc42 or PAK1 to induce morphology 
changes. The second row of images are cells that were additionally treated with 10 nM 
EGF to stimulate morphology changes. All other cells were not treated with EGF. Cells 
were stained with FITC-labeled anti-PLD6 antibody and either MitoTracker-RFP or 
TRITC-labeled phalloidin stain. Images were taken at 100x magnification and 
photographs were merged using Adobe Photoshop software.  
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Figure 42. Cell invasion of cells overexpressing or silencing PLD6. Matrigel-based 
invasion assays were performed using either MCF-7 (A) or MDA-MB-231 (B) cells. 
Both cell lines were transfected with PLD6 plasmid, however, only the PLD6-
overexpressing MDA-MB-231 cells showed an increase in cell invasion. (C) PLD6 was 
silenced in MDA-MB-231 cells using siRNA and these cells exhibited a drastic reduction 
in cell invasion. Error bars represent SEM and a probability (P) of <0.05 indicates 
significance using the student t-test. A significant increase is denoted by (*) while a 
significant decrease is denoted by (#).  
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Figure 43. Successful overexpression and silencing of PLD6. (A) qRT-PCR of pld6 
mRNA levels in MCF-7 and MDA-MB-231 cells. Cells transfected with pld6-encoding 
plasmid show a significant increase in PLD6 mRNA. (B) Western blot of PLD6 protein 
levels in MDA-MB-231 cells treated with siRNA against PLD6 or a scramble siRNA 
(siNEG). PLD6 protein is decreased in the presence of 50 nM siPLD6. Further, PLD1 
and PLD2 protein levels remain unchanged in the presence of 50 nM siPLD6 relative to 
scramble siNEG. (C) Western blot of PLD6 protein in MCF-7 and MDA-MB-231 cells 
when transfected with PLD6 plasmid. β-Actin was used as a loading control.   
C 
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CHAPTER 6. DISCUSSION 
 
In this dissertation, the signaling of three members of the PLD family and how 
their dysregulation promotes breast cancer cell invasion and survival were investigated. 
In the first Aim, the post-transcriptional regulation of the classical PLD isoforms, PLD1 
and PLD2, were explored. Specific miRNAs present in non-cancerous cells downregulate 
PLD protein and this regulation is lost in invasive breast cancer cells. Furthermore, the 
addition of exogenous miRNAs (miR-203, -887, -3619, and -182) to MDA-MB-231 cells 
downregulates PLD protein, and this regulation is lost in invasive breast cancer cells. The 
addition of exogenous miRNA to MDA-MB-231 cells downregulates PLD protein 
production and subsequently inhibits cell invasion. In Aim 2, PLD expression and 
regulation under nutrient starvation was investigated, a condition that favors the 
epithelial-to-mesenchymal transition that may lead to cell invasion. Finally, in Aim 3, the 
role of PLD6 in breast cancer cell invasion was investigated, including the effect of 
starvation and EGF signaling on PLD6 expression and subcellular localization. Overall, 
this study contributes to increasing the understanding of the molecular regulation and 
signaling of the PLD family in breast cancer invasion. 
A connection between EMT markers and the expression of four miRNAs 
mediated by the signaling enzyme PLD was shown. Low aggressive MCF-7 and BT-474 
breast cancer cells have low endogenous PLD enzymatic activity and cell invasion 
concomitant with high expression of miR-203, -887, and -3619 (that decrease 
endogenous PLD2 levels and translation of a luciferase reporter) and miR-182 (targeting 
PLD1). The combination of miRNAs abolished ~90% PLD enzymatic activity. 
Conversely, post-EMT MDA-MB-231 and BT-549 cells have low levels of expression of 
the same miRNAs and high levels of PLD1/2 expression and high aggressiveness. The 
latter was reversed by ectopically transfecting the miRNAs, which was negated by 
silencing miRNAs with specific siRNAs. In this study, a molecular mechanism was 
determined where E-cadherin triggers expression of the miRNAs in pre-EMT cells, 
whereas vimentin dampens expression of the miRNAs in post-EMT, invasive cells. This 
novel work identifies for the first time that a set of miRNAs that is activated by a major 
pre-EMT marker and deactivated by a post-EMT marker, boosts the transition from low 
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invasion to high invasion, as mediated by the key phospholipid metabolism enzyme PLD. 
The present data identify the mechanism of action of pre- and post-EMT drivers 
on breast cancer cell invasion through a discrete set of micro-RNAs that directly regulate 
the lipid-signaling enzyme PLD. Here, I propose a model by which regulation of PLD 
protein expression was disrupted in highly aggressive MDA-MB-231 breast cancer cells. 
Four microRNAs were identified and shown to regulate either PLD1 or PLD2 
mammalian isoforms with evidence to suggest direct binding to the respective PLD-
3’UTR. The tumor suppressor-like miRNAs had endogenously decreased levels of gene 
expression in highly aggressive MDA-MB-231 breast cancer cells compared with HMEC 
non-cancerous breast cells. This decrease in miRNA gene expression correlated with 
increased PLD protein expression. By overexpressing the tumor suppressor-like 
miRNAs, miR-203, -887, and -3619, targeting PLD2, and miR-182 targeting PLD1, the 
respective PLD protein expression was decreased as well as PLD enzymatic activity in 
MCF-7 and MDA-MB-231 breast cancer cells. These experiments suggest a post-
transcriptional regulation of PLD by these tumor suppressor-like miRNAs. Based on 
these data, I propose a mechanism of direct binding of these miRNAs to their respective 
PLD mRNA and subsequent inhibition of protein expression. Additionally, I propose this 
mechanism occurs naturally in non-cancerous HMEC breast cells, which is dysregulated 
in highly invasive MDA-MB-231 breast cancer cells. 
MicroRNA-loaded RISC can inhibit protein translation by either inhibiting 
ribosomal function or inducing the degradation of mRNA (136). Zhang et al. 
demonstrated that the miRNA-loaded RISC can associate with the deadenylase PARN 
and carry PARN to target mRNA where PARN cleaves the poly(A) tail thereby 
destabilizing the mRNA (136). This mechanism of miRNA-mediated deadenylation has 
also been shown with other deadenylases including the Ccr4-Not and Pan2/Pan3 
complexes (137,138). Further investigations into the mechanism of action of miRNA-
mediated downregulation of PLD in breast cancer are necessary.  
Phospholipase D is a critical membrane protein at the center of complex signaling 
networks increasing both cell movement and cell proliferation. PLD acts through protein-
protein interactions with signaling molecules including Grb2, Rac2, WASP, S6K, and 
JAK3 and also through the enzymatic production of a vital lipid secondary messenger, 
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phosphatidic acid (28). PLD has been implicated in perpetuating cancer progression by 
serving as a cell survival signal and by facilitating invasion, the first step in metastasis 
(28,139,140). Elevated PLD protein expression and activity have been associated with 
more advanced cancer cell lines (140-143). 
Furthermore, overexpressing these miRNAs confirmed the hypothesis that the 
tumor suppressor-like miR-203, miR- 887, miR-3619, and miR-182 were able to 
diminish the invasively aggressive properties of MDA-MB-231 cells. Suppressing the 
PLD-mediated effect on cell invasion was presumably accomplished through inhibition 
of PLD2 translation. As a consequence the well-known effects of PLD on phosphatidic 
acid-mediated cell migration would be inhibited, as well as the formation of protein-
protein interactions of PLD and proteins of the cell motility machinery (namely, Grb2, 
Wasp, Arp3, and actin). Silencing these miRNAs (miR-203 and -182) could reverse their 
inhibitory effect on cell invasion. Thus, I report for the first time specific miRNAs that 
play a major role in breast cell cancer biological activity to explain the role of PLD. 
As EMT progresses and breast cancer cells became more mesenchymal, a set of 
miRNAs specific for PLD is down-regulated as is the PLD gene, while protein expression 
is increased. By silencing a pre-EMT marker protein (E-cadherin), the expression of the 
tumor suppressor-like miR-3619 and miR-182 were diminished. Conversely, expression 
of these miRNAs was increased by silencing the post-EMT marker vimentin. Therefore, 
these tumor suppressor-like miRNAs are under regulatory control of the EMT status of 
the cell, and thus cells undergoing EMT prepare for invasion by accumulating PLD 
protein via downregulation of these miRNAs. Additionally, one miRNA can have 
numerous mRNA targets within a cell and these miRNA could target other EMT 
effectors. TargetScan was used to predict miRNA binding of well known EMT effectors 
including vimentin, fibronectin, E-cadherin, EGFR, β-catenin, Snail, Slug, Twist1, Zeb1, 
and Zeb2. Notably, several miRNA studied herein were also predicted to target some of 
these mRNA (TargetScan). MicroRNA-203 is predicted to target the mRNA of 
fibronectin, E-cadherin, EGFR, Slug, Twist, and Zeb1. With the exception of E-cadherin, 
the other predicted targets all promote EMT and cell invasion. Additionally, miR-182 is 
predicted to target fibronectin, Slug, Twist, and Zeb2, all of which promote EMT. This 
suggests miR-203 and -182 could exert more influence in suppressing EMT through 
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targeting multiple targets and furthermore, could be beneficial therapeutic agents. In this 
way, miRNA can be useful therapeutic agents to target multiple pathways 
simultaneously. In contrast, silencing RNA (siRNA) are also being explored as 
therapeutics in cancer treatment (144) and posses greater specificity in their target. 
Therefore, siRNA can be used to target specific oncogenes or can be designed for patient-
specific mutations (144). However, siRNA are less stable that miRNA in the vascular 
circulation and thus delivery systems are important considerations. The long-term 
application of this study could be realized as a potential clinical application in assessing 
the efficacy of tumor suppressor-like miRNA-mediated down-regulation of PLD in 
combination with inhibitors of PLD activity directed toward inactivating the aggressive 
cell invasion phenotype. 
In the second Aim, the effect of starvation on PLD and miRNA regulation were 
investigated. It is well-known that mTOR is a strong inhibitor of apoptosis. One of the 
intracellular activators of mTOR is PA. The activity of the enzyme that synthesizes PA, 
PLD, is increased in cancer cells subjected to serum deprivation, making PLD a 
“survival” or “stress response” protein (27). However, the mechanism for this increase 
during starvation has remained unsolved. PLD rises and decreases with nutrient 
starvation while miRNA expression steadily rises with time of starvation, and miRNAs 
are responsible for the decrease of PLD expression. The interaction between PLD/PA and 
the microRNAs is biphasic and depends on a feedback loop that is absent in noncancer 
cells.  
A new mechanism of regulating the response to nutrient starvation by microRNAs 
targeting PLD is reported here. PLD plays an important role in the metastasis of breast 
cancer cells (27), and several protein-protein interactions relevant to cell migration have 
been discovered. The aim of the current study was to identify and further characterize 
microRNAs, which bound with imperfect complementarity to the 3’UTR of PLD mRNA, 
leading to repression of its translation. Additionally, the effect, or biological function, of 
nutrient starvation on miRNA-mediated post-transcriptional regulation of the signaling 
enzyme PLD was determined. 
It is known that several miRNAs can regulate the expression of a particular 
protein, presented here are a specific set of miRNAs that affect PLD translation. In 
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combination with current software, it was determined that miR-182 was predicted to bind 
to PLD1 and that miR-203, miR-887, and miR-3619-5p were predicted to bind to PLD2. 
Determining the regulatory role of these miRNAs on PLD protein expression in breast 
cells, both noncancerous and cancerous, was the goal. 
Multiple studies describe the dysregulation of miRNAs in cancer tissue and cell 
culture compared to noncancerous samples (145-148). Most often, miRNAs are repressed 
in cancer, as is described here with the PLD-regulating miRNAs. However, there have 
been examples of oncogenic miRNAs that are overexpressed in cancer, such as miR-155 
and miR-21, where overexpression was sufficient to induce lymphomagenesis in mice 
(105,149). MicroRNAs have many roles in cell function, are pivotal intersections of 
communication, and thus have been implicated in many areas of cancer disease, including 
initiation (105,149), proliferation, metastasis, drug resistance (150), and biomarkers 
(147,148). This highlights the crucial role of miRNAs in cancer development and 
progression. I proposed in this study that miRNA regulation of PLD protein expression is 
a vital component of the nutrient depletion stress response in breast tumor cells. 
As shown by the Foster and Frohman groups, starvation and lack of nutrients in 
cancer cells initiate a survival program (34,151-154). Cells under hypoxic conditions and 
that also lack nutrients have elevated PLD activity. The endogenous levels of PLD 
expression and phospholipase activity in luminal MCF-7 and claudin-low MBA-MB-231 
breast cancer cells followed a biphasic pattern with a maximal expression at 6 to 12 h 
after starvation and a decrease below control levels at 24 h. After 12 to 24 h of starvation, 
microRNAs were elevated in MDA-MB- 231 cells and MCF-7 cells 20- to 40-fold, 
respectively, and after 24 h of starvation, PLD2 protein mass was minimal. The miRNA 
expression levels changed prior to significant decreases in PLD2 protein mass. The four 
PLD-specific miRNAs (miR-203, miR-182, miR-3619-5p, and miR-887) played a key 
role in decreasing PLD protein levels. Still, all four of these miRNAs that had elevated 
expression (miR-203, miR-887, miR-3619, and miR-182) could in combination be 
responsible for influencing PLD2 protein levels. 
These data are consistent with the current model for phosphatidic acid (PA) 
activation of mTOR. PA, the enzymatic product of PLD, binds and activates mTOR 
(155,156). The activated mTOR pathway induces increased cell growth and proliferation 
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(41). As a highly sensitive stress response protein, the PLD protein mass initially 
increased during nutrient starvation, which would facilitate cell migration. Additionally, 
an increase in PA results in mTOR-induced cell growth. After prolonged starvation, it is 
thought that cells can no longer afford the cost of increased mTOR activity and cell 
growth associated with increased PLD and PLD-mediated cell migration. Therefore, I 
propose a negative-feedback mechanism wherein cells undergoing prolonged starvation 
increase gene expression of PLD-regulating microRNAs, resulting in the downregulation 
of PLD protein mass. 
Starvation induces autophagy, which is associated with protein degradation 
(157,158). It is still possible that PLD2 protein degradation could be mediated by an 
additional mechanism in parallel with miRNAs. For example, autophagy is coupled with 
a reduction in histone H4 lysine 16 acetylation (H4K16ac) via downregulation of hMOF, 
a histone acetyltransferase (159,160). If hMOF is degraded (leading to a decrease in 
H4K16ac at the PLD2 promoter), then this could influence the levels of PLD2 protein 
levels. 
The p53 mutation status is one of the molecular differences between MCF-7 
(wild-type p53) and MDA-MB-231 cells. The p53 replacement mutation at codon 280 is 
located in the DNA binding domain of p53, which causes altered transcriptional activity. 
MicroRNA-203 (161) and miR-182 expression is regulated by p53. In cardiac fibroblasts, 
serum starvation resultes in an elevated expression of p53 (162). Upon starvation, levels 
of p53 might be altered differentially in MCF-7 cells and MB-231 cells. These altered 
p53 levels might influence miRNAs and also PLD2 levels. 
Loss or gain of function of specific miRNAs probably contributes to breast 
epithelial cellular transformation and tumorigenesis (163). A model of starvation effects 
on PLD in cancer cells by the David Foster group indicates that cells in the core of a 
tumor mass become hypoxic and increase the environmental pressure to leave the tumor, 
seeking a new environment; these cells resemble mesenchymal cells, and the expression 
of PLD is augmented (164). Future work should investigate whether the miRNAs that are 
documented here are downregulated under starvation and hypoxic conditions. 
Evidence is provided here for a negative feedback loop, where PLD induction 
upon starvation would lead to increased PA. PA signaling could induce expression of 
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miRNAs, which in turn inhibit PLD2 translation. The physiological relevance for breast 
cancer cells is that PA can activate cell invasion and then, due to the negative feedback, 
can deprive mTOR and S6K of their natural activator, prevent inhibition of apoptosis, 
and survive nutrient deprivation, which normal cells cannot do. It seems logical there 
may be a common mechanism of altering the expression of these four miRNA in starved 
cells or cells treated with PA. All four miRNA are located on different chromosomes and 
little is currently known about the promoter regions of each miRNA. The exception is 
miR-203, which is dysregulated in numerous cancer types. For example, the miR-203 
was found to be downregulated in metastatic breast cancer cell lines due to 
hypermethylation of the CpG island in its promoter (165). CpG islands are frequently 
seen in promoters of tumor suppressor genes and therefore epigenetic changes of the four 
miRNA genes could be a possible regulatory mechanism in breast cancer cells. 
Furthermore, Ding et al. (166) showed that the EMT-promoting transcription factor Slug 
(SNAI2) can directly bind and repress the miR-203 promoter. Additionally, Zhan et al. 
demonstrated that Snail (SNAI1) transcription factor can directly bind and repress the 
miR-182 promoter in breast cancer cells (167). Snail is a well-known driver of EMT and 
one or several of the EMT transcription factors may act upon the promoters of these four 
miRNA in breast cancer cells. The Cambronero lab previously showed that PA can bind 
to the transcription factor PPARα (168) and it would be interesting to investigate binding 
of PA to other transcription factors including EMT drivers. A better understanding of 
PLD regulation in these cells could also lead to the design of better treatment options. 
The third specific Aim, was designed to understand an understudied isoform of 
the PLD family, PLD6. Most well-characterized for its role in spermatogenesis, PLD6 
was identified through microarray analysis to be upregulated in some breast cancer tissue 
samples. Located in the outer mitochondrial membrane, PLD6’s catalytic activity 
promotes mitochondrial fusion and discourages apoptosis, which would be advantageous 
for cancer cells. Furthermore, von Eyss et al. (131) found that PLD6 is under direct 
regulation of the transcription factor c-myc, which is mutated and/or upregulated in many 
cancers. Myc is well known for its role in promoting cell growth and moreover, mitogen 
signals such as EGF activate myc. In previous two aims, it was demonstrated that PLD1 
and PLD2 are influenced by EGF as well as starvation conditions. PLD1 and PLD2 are 
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stress reponse proteins and their increased expression and activity result in increased 
cancer cell invasion. Thus I hypothesized that PLD6 has a similar role in breast cancer. 
Namely, does PLD6 catalytic activity respond to the same signaling pathways and is its 
activity related to cell invasion.  
For the study of PLD6, the same breast cell lines as in the previous two aims were 
used, MDA-MB-231, MCF-7 and HMEC cells. Elevated PLD6 mRNA and protein 
expression in MDA-MB-231 cells were observed compared to the non-cancerous HMEC 
cells. Further, PLD6 detection in MCF-7 cells was none to very minimal. This data is 
consistent with elevated expression of myc in MDA-MB-231 cells compared to MCF-7 
cells. It is interesting that MCF-7 cells express less PLD6 than even non-cancerous 
HMEC cells. While MCF-7 cells are a less invasive cell line, they are more rapidly 
proliferating than non-cancerous cells. Because PLD6 promotes increased ATP 
production, it is interesting that PLD6 expression would be lower in MCF-7 cells than 
HMEC cells. MCF-7 cells likely have alternative methods of coping with increased 
energy demands such as increased glycolysis. 
In examining xenotransplanted MDA-MB-231 tumors from mice, PLD6 staining 
was evident near the tumor periphery. Wild type tumors showed greater PLD6 staining 
than the less aggressive shPLD2 tumors, consistent with the notion of PLD6 promoting 
breast cancer cell invaion. Furthermore, this finding suggests a role for PLD6 in a tumor 
environment, which is more complex than cancer cells in cell culture. The tumor 
microenvironment is composed of cancer cells as well as non-cancerous cells including 
fibroblasts, immune cells, adipocytes, and epithelial cells, as well as the supporting 
collegen and tissue (134). Cross talk between cancer cells and the tumor 
microenvironment plays a significant role in tumor growth (134). A pertinent example is 
how oxidative stress in tumor stromal cells promotes breast cancer development and 
progression.  Studies have shown that ROS produced by tumor stromal cells acts via 
paracrine signaling promoting cancer cell tumorigenic transformation, resistance to 
apoptosis, and cell migration (169,170). Additionally, oxidative stress promotes the 
transformation of tumor fibroblast to myofibroblast, which are highly mobile and 
contractile cells expressing mesenchymal markers (134,171). Myofibroblasts promote 
tumor initiation and progression by generating high levels of ROS and secretion of 
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growth factors (134,172,173). A major producer of ROS is mitochondrial oxidative 
phosphorylation and in a normal cell, excessive ROS leads to mitophagy and autophagy. 
Autophagy of tumor stromal cells provides amino acids, nucleic acids, and fatty lipids to 
cancer cells, promoting their growth (134,174-176). Furthermore, breast cancer cells 
exhibit increased mitochondrial oxidative activity compared to tumor-associated 
fibroblasts (177). PLD6 promotes mitochondrial fusion thereby inhibiting mitophagy and 
therefore, I expect PLD6 protein to be elevated in cancer cells and less expressed in 
tumor stromal cells. PLD6 expression likely varies throughout disease progression. For 
instance, PLD6 would likely favor ROS generation seen in tumor-associated 
myofibroblasts. With time, cellular mechanisms regulating mitophagy and autophagy in 
the myofibroblasts would likely alter PLD6 expression. Conversely, in cancer cells, 
increased mitochondrial activity and avoidance of mitophagy perseveres despite 
accumulating ROS.  
Under basal conditions, PLD6 co-localized with mitochondria in both HMEC and 
MDA-MB-231 cells, consistent with published data. When MDA-MB-231 cells were 
treated with starvation alone or starvation + EGF, PLD6 adopted a more diffuse 
localization throughout the cytoplasm. Unlike PLD1 and PLD2, PLD6 protein levels did 
not change after starvation or EGF treatment. Both starvation and EGF promote cell 
migration and thus the re-distribution of PLD6 could be beneficial to cell migration. It is 
possible that the more diffuse localization of PLD6 indicates a relocalization of 
mitochndria in response to starvation or EGF. Mitochondria are found at the leading edge 
of migrating cells and distribution of mitochondria throughout a migrating cell would 
provide ATP diffusely for use in migration. By IF microscopy, it was unclear if the PLD6 
at the cell periphery was localized to mitochondria. The mitochondrial signal was so 
strong in the perinuclear region, that any mitochondrial staining in the thinner 
lamellipodia could be masked. Fluorescent confocal microscopy would be better suited to 
answer such a question.  
MDA-MB-231 cells starved and treated with EGF also appeared to have a nuclear 
PLD6 staining upon IF microscopy. To my knowledge, PLD6 has not been reported to be 
in the nucleus and a PLD6 NLS has not been validated. However, reported overlap of 
typical MLS and NLS sequences could indicate that a portion of the MLS on PLD6 could 
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function as a NLS. Furthermore, PLD6 functions as both a lipase and an endonuclease in 
the processesing of piRNA. Thus, nuclear PLD6 is an intriguing notion and its nuclease 
activity may be involved in RNA processing. Nuclear fractionation of MDA-MB-231 
cells treated with starvation and EGF and fraction analysis by Western blot did not detect 
the presence of PLD6 in the nuclear fraction. The original nuclear marker used was 
Histone H3 and because it is bound to chromatin, it is difficult to detect the occurrence of 
any protein leakage from the nuclear fraction during the fractionation process. A soluble 
nuclear protein p53, was used to further investigate this possibility. p53 protein was 
observed in the cytoplasmic fractions, which may indicate protein leakage from the 
nuclear fractions. An additional problem could be the polyclonal PLD6 antibody used. 
The antibody could have non-specific binding to a different nuclear protein. However, a 
monoclonal PLD6 antibody against a specific epitope is not currently commercially 
available. Using confocal microscopy, PLD6 antibody signal was found within the 
nucleus in a population of cells. An additional experiment would be overexpressing myc-
tagged PLD6 plasmid and probing with a myc-tag specific antibody with strong signal 
specificity. However, this approach would not detect endogenous protein and it is 
possible endogenous protein behaves differently than overexpressed protein. 
Using confocal microscopy, I did observe PLD6 staining in the nuclear regions of 
cells. However, this staining was only present in a small population of cells treated with 
EGF, suggesting EGF stimulation may not be sufficient to induce PLD6 nuclear 
localization. Alternatively, PLD6 nuclear localization could be cell cycle dependent. 
PLD6 functions as both a lipase and an endonuclease and both of these activities could be 
critical in a growing cell preparing to divide. PLD6’s mitochondrial lipase activity and 
production of PA is known to promote mitochondrial fusion generating larger 
mitochondria able to meet the energy demands of a growing cell. Additionally, PLD6 
functions as an endonuclease on precursor piRNA. piRNA are important in repressing 
transposons in spermatocytes and maintaining DNA integrity. This function of PLD6 has 
been reported in the nuage of spermatocytes, the mitochondrial-rich perinuclear region, 
during meiosis (69). An interesting study would be to synchronize cells and observe 
PLD6 subcellular localization in different phases of the cell cycle.  
Overexpression of PLD6 increased cell invasion in MDA-MB-231 cells but failed 
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to elicit any change in cell invasion in MCF-7 cells. This suggests PLD6 alone is not 
sufficient to promote cell invasion or MCF-7 cells have a mechanism of counteracting the 
effects of PLD6. A specific assay to determine total PA levels within the cell as well as 
PA co-localization with PLD6 would be beneficial. This could demonstrate if 
overexpression of PLD6 results in increased cellular PA. Additionally, it could help 
correlate increased cell invasion with an increase in PLD6 lipase activity. First, as 
discussed above, MDA-MB-231 cells have higher expression levels of the transcription 
factor myc. Myc protein directly binds to the PLD6 promoter and increases PLD6 
transcription, contributing to the elevated levels of PLD6 in MDA-MB-231 cells. In 
addition, myc promotes the transcription of many genes involved in cell proliferation and 
cell growth including cyclins, ribosomal RNA and proteins. To date, there is no literature 
suggesting myc regulates PLD1 or PLD2, however, PLD1 and PLD2 promote that 
stabilization of myc protein (178). PLD6 acvitity promotes mitochondrial fusion and 
presumably increases oxidative phosphorylation and ATP production within the cell. 
Thus, it could be that the cell uses this energy to power cytoskeletal reorganization and 
other processes necessary for cell invasion, which the machinery is already present in 
MDA-MB-231 cells but not MCF-7 cells. In addition, EGF was as a chemoattractant in 
the invasion assays. MDA-MB-231 cells express higher levels of EGFR than MCF-7 
cells. Further, EGF signaling stimulates myc, but also PLD1 and PLD2 activity. Data in 
Aim 1 showed that PLD1 and PLD2 both promote cell invasion and they are both 
expressed at higher levels in MDA-MB-231 cells. Thus, it is possible that PLD6 
promotes cell invasion in a cell that is capable of invading, such as a cell that has already 
undergone EMT.  
Overall, this study demonstrated that three members of the PLD family are 
upregulated in invasive breast cancer cells. The classical PLD isoforms, PLD1 and PLD2, 
are regulated by at least four microRNA in health breast cells. However, in cancer cells 
that have undergone EMT, these miRNAs are downregulated, promoting the increased 
protein translation of PLD1 and PLD2. Further, PLD1 and PLD2 are stress response 
proteins, and are increased initially upon serum starvation. During prolonged starvation, 
the same miRNA are upregulated and serve to downregulate PLD1 and PLD2 protein. 
Additionally, PLD6 is a mitochondrial protein whose catalytic activity promotes 
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mitochondrial fusion. Under certain conditions, PLD6 may localize to the nucleus and/or 
the leading of invading cells. The overexpression of PLD6 in MDA-MB-231 cells 
increased the cell invasiveness while silencing PLD6 decreased cell invasion. 
Interestinly, this effect was cell line dependent, as no effect was observed with 
overexpressing PLD6 in MCF-7 cells. In conclusion, the dysregulation of the three PLD 
isoforms studied herein contribute to breast cancer cell invasion.  
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